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ABSTRACT 
 
 
The temporospatial controlled delivery of growth factors is crucial to trigger the desired healing mechanisms in 
target tissues. The uncontrolled release of growth factors has been demonstrated to cause severe side effects in its 
surrounding tissues. Thus, the first working hypothesis was to tune and optimize a newly developed multiscale 
delivery platform based on a nanostructured silicon particle core (pSi) and a poly (dl-lactide-co-glycolide) acid 
(PLGA) outer shell. Both components of the resulting composite microspheres (PLGA-pSi) contributed to control 
the release kinetics of proteins. In a murine subcutaneous model, the platform was demonstrated to be fully 
tunable for the temporal and spatial control release of the payload. PLGA-pSi was able to retain the payload for 
weeks, thus avoiding the initial burst release found in most of the current drug delivery systems.  
The ideal scaffold for regenerative medicine should concurrently mimic the structure of the original tissue from 
the nanoscale up to the macroscale and recapitulate the biochemical composition of the extracellular matrix 
(ECM) in space and time. Thus, a multiscale approach was followed in a multicompartment collagen scaffold, to 
selectively integrate different sets of PLGA-pSi loaded with reporter proteins. Through the preservation of the 
structural cues of the functionalized collagen scaffold at the nanoscale and microscale, its macroscopic features 
(pore size, porosity, and swelling) were not altered. Additionally, the spatial confinement of the microspheres 
allowed the release of the reporter proteins in each of the layers of the scaffold. Finally, the staged and zero-order 
release kinetics enabled the temporal biochemical patterning of the scaffold. The versatile manufacturing of each 
component of the scaffold resulted in the ability to customize it to better mimic the architecture and composition 
of the tissues and biological systems. 
However, the clearance of delivery systems from implants is currently a limiting step in the development of 
biomaterials functionalized with delivery systems for tissue engineering applications. Thus, the last step of this 
PhD project was to test if by fully embedding PLGA microspheres in a highly structured and fibrous collagen-
based scaffold (camouflaging), it was possible to prevent their early detection and clearance by macrophages. It 
was further studied whether such a camouflaging strategy was efficient in reducing the production of key 
inflammatory molecules, while preserving the release kinetics of the payload of the PLGA microspheres. Results 
demonstrated that the camouflaging allowed for a 10-fold decrease in the number of PLGA microspheres 
internalized by macrophages, suggesting that the 3D scaffold operated by cloaking the PLGA microspheres. 
When the production of key inflammatory cytokines induced by the scaffold was assessed, macrophages' response 
to the PLGA microspheres-integrated scaffolds resulted in a response similar to that observed in the control (not 
functionalized scaffold) and the release kinetic of a reporter protein was preserved. This data suggested that the 
platform herein proposed is an efficient system to camouflage delivery systems in 3D collagen-based scaffolds, 
preventing their early detection and internalization by macrophages, thus contributing to preserve the release 
kinetics of their payload.  
In summary, this PhD thesis consisted of the development of 3D biomimetic scaffolds integrated with 
nanostructured carriers of bioactive molecules, able to escape early macrophage response, ultimately allowing for 
the spatial and temporal control over the release kinetics of their payload, for tissue engineering applications.  
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
 
 
Tissue engineering allows restoring or favoring the recovery of damaged tissues and organs, and it has 
been envision the possibility to reduce the need for organ replacement [1]. Even though fewer than five 
engineered tissues have been approved by the Food and Drug Administration (FDA), more than 70 
companies are spending a total of $600 million per year to develop new products (2). There are still many 
technical challenges to overcome before we create “off-the-shelf” tissues that represent the translation of 
scientific discoveries into treatments for millions of patients. The successful large-scale production of 
engineered tissues requires an adequate source of healthy expandable cells, the optimization of scaffolds, 
and the creation of bioreactors, which mimic the environment of the body and that are amenable to scale-
up. Additional challenges include the preservation of the product so that it has a long shelf-life and the 
successful use of various approaches to prevent tissue rejection [1].  
Innovative regenerative approaches and devices can be designed by taking inspiration from nature, which 
surrounds us with a multitude of organisms endowed with extraordinary performances. The shape of 
organisms, animal coat patterns and seashells are becoming more often an inspiring source. Material 
scientists have been vastly learning from Nature; for example structures found on water lilies, on butterfly 
wings or marine organism’s skeleton could find application to construct water-repellant materials, 
photonic structures or optical fibers [2]. Moreover, biomaterials found in nature not only have very 
interesting properties but are also inspiring in the way they are made.  
Biomimicry is a term used to describe different kinds of therapeutic/biomedical approaches: mimicking 
nature form or function, organization and biomolecular working mechanism are just a few examples of 
this new research field [3]. Mimicking nature’s form or function can be applied as a paradigm in the 
tissue engineering applications. 
 
1.1.  Mimicry of the extracellular matrix composition and its functions 
The final goal of tissue engineering is to create neo-tissues similar in architecture, function and 
compatibility to native human structures [4]. Although this approach is very promising, many challenges 
have to be addressed to achieve effective tissue regeneration through the reproduction of complex 
mechanisms of living system [5]. Observation and understanding of the fundamentals operating in native 
tissue represents the starting point to develop biohybrid artificial substitutes. Inside a tissue, cells of 
different phenotypes are interconnected by a complex network of macromolecules comprising of proteins 
and polysaccharides secreted by the cells themselves. This natural environment refers to the extracellular 
matrix (ECM) that has the role to structurally and functionally organize the overall tissue.  
 
1.2.  The extracellular matrix: a modulator of cell activity in tissues  
The ECM serves as a channel for cell-cell communication. It is enriched with a number of cell surface 
receptors (e.g. integrins, laminin, syndecans) and structural proteins (e.g. collagens, laminins, fibronectin, 
vitronectin and elastin, which allow adhesion, migration, proliferation and differentiation [6]. Artificial 
two- and three-dimensional extracellular scaffolds are typically employed by tissue-engineering to 
reproduce a native functional tissue and thereby improve the recovery of the patient and tissue 
regeneration [7]. Such an artificial environment, meant to support different processes in tissue formation, 
the ECM should ideally: i) provide structural support for cells residing in that tissue to attach, grow, 
migrate and respond to signals; ii) give the tissue its structural and mechanical properties associated with 
the tissue functions; iii) provide bioactive cues to the residing cells; iv) act as a reservoir of growth factors 
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(GF); v) provide a degradable environment to allow neovascularization and remodeling in response to 
developmental, physiological and pathological challenges (e.g., homeostasis and wound healing) [8]. 
Because of the tight connection between the cytoskeleton and the ECM achieved through cell surface 
receptors, cells sense and respond to the mechanical properties of their environment by converting 
mechanical signals into chemical signals [9, 10]. Consequently, the biophysical properties of ECM 
influence various cell functions, including adhesion and migration. Moreover, the fibrillar structure of 
matrix components have been demonstrated to alter cell behavior by bringing about adhesion ligand 
clustering [11]. Structural ECM features, such as fibrils and pores, are often of a size compatible with 
cellular processes involved in migration, which may influence the strategy by which cells migrate through 
the ECM [12].  
 
1.3.  Artificial extracellular matrices for tissue engineering applications  
The principles of biomimicry are based on strict adherence to the proper replication of natural science as a 
medium for promoting cellular repair. This coupled with control over the chemical and physical cues of 
the scaffold will provide the proper environment for cells to integrate and proliferate with the surrounding 
recipient tissue site. Demonstrating control over the platform for cell growth is important to achieving 
multi-functionality [13]. In order to create an artificial extracellular matrix a wide range of options exist 
(natural, synthetic and hybrid materials).  
 Natural materials have biological activity and biocompatibility. The degradation products of 
these kinds of materials are natural metabolic products as sugars, aminoacids or minerals that 
reduce the possibility of cytotoxicity and inflammation [14]. They can be grouped in 3 classes: i) 
ceramics and ceramics composites (shells, bones, material with mineral component) ii) 
biopolymer and biopolymer composit (ligament and silk) iii) cellular materials (feathers, wood, 
cancellous bone).  
 Biomimetic Synthetic materials represent biologically multifunctional hydrogel-based structures, 
synthesized or not under physiological-like conditions [15, 16], that mimic natural ECMs at the 
biochemical and biophysical level such as poly(ε-caprolacton (PCL), poly(lactic-co-glycolic) acid 
(PGLA), and Polyethylene glycol (PEG). 
 Hybrid materials are systems composed by at least two distinct classes of material (synthetic and 
biological), for example, synthetic polymers and proteins domains. The combination results in 
new materials that possess novel properties [17]. 
Although natural biomaterials have proved effective in many basic and clinical applications [18] synthetic 
materials more effectively control their physical and chemical properties and can be further modified 
through biochemical means [19].  
 
1.4.  Surface modifications of biomaterials 
For the successful design of materials to serve as artificial ECMs, knowledge of molecular interactions 
that occur within the tissues and between the cells and the ECM is required [20-22] (Figure 1.1). The 
composition, structure, and manufacturing methods could affect the structural and mechanical properties 
of the tailored scaffold and the in vivo degradation [23]. Attempts to determine synthetic material surface 
modifications and to improve the modulation of cell–material interactions have led to the alteration of 
physicochemical features of biomaterials like chemistry [24] or topography [25-27]. Current methods of 
biomaterial functionalization include specific surface coatings and the incorporation of bioactive 
molecules such as adhesion sites, growth factors, anti-inflammatory mediators or drugs, either alone or 
combined [28, 29]. Biomaterial surface functionalization can be performed either by physical or by wet 
chemical treatments. Physical modifications include electron-beam or UV-radiation-induced coupling of 
molecules [8] [6], surface-radical-induced coupling of molecules, and functionalization by non-
polymerizing plasma-generated species. Each of these approaches has specific advantages and 
disadvantages concerning the variability, selectivity, and stability of the obtained functionalization, as 
well as the question of polymer structure retention or destruction. At present, most functionalization 
approaches result in surfaces that exhibit a mix of different functional groups [9-13]. It is notable that 
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plasma activation offers a convenient way to alter the surface properties, such as bioactivity and 
hydrophilicity, or hydrophobicity, while retaining the favorable bulk properties such as biostability, or 
biodegradability [14, 19].  
Taking into account the multifunctional and the nature of biological components, the major challenge into 
this direction is a chemical one: the need to proceed through bio-orthogonal reactions and under the 
benign reaction conditions that would preserve and respect the functionality and structure of biological 
building blocks. In 2001, Sharpless and coworkers [17] introduced the concept of “click chemistry” that 
successively had an wide impact on the chemical 
community driving the design of new generation 
of synthetic biomaterials [30]. These versatile 
reactions represent a formidable way to engineer 
hydrogel networks, decorated 2D cell culture 
surfaces and 3D scaffold. It also provides control 
over the conformation of the protein or peptide 
immobilized, thereby maximizing its bioactivity. 
Finally, the evolution of click-chemistry with the 
Diels−Alder Click Immobilization is the new era 
of “reagent-free” click reaction that does not 
require catalyst, photoinitiator, or radical initiation 
[31-33].  
1.4.1. Integrin adhesion sites  
The knowledge of cell adhesion molecules 
(CAMs) is already being widely investigated [34]. 
Integrins are proteins known to be involved in the 
process of cell adhesion, motility, growth, shape and differentiation [35]. The functionalization of 
biomaterials with short sequences derived from ECM proteins has been shown to improve cell-specific 
adhesion and function. The most commonly used peptides are derived from proteins like fibronectin (e.g. 
RGD, KQAGDV, REDV and PHSRN), laminin (e.g. IKLLI, LRE, LRGDN, PDGSR, IKVAV, LGTIPG, 
and YIGSR), collagen (e.g. DGEA, GFOGER) and elastin (e.g. VAPG). The most widely used is the 
arginine-glycine-aspartate (RGD) sequence, a ubiquitous receptor adhesion motif found in most ECM 
proteins [30]. RGD modified surfaces have been used in a variety of applications such as engineering 
neuronal tissue [36], improving human embryonic stem cells growth in vitro [30] and increasing the 
biocompatibility of orthopedic materials [37]. Regarding the integrin domain functionalization some key 
aspects need to be taken into account. The density and presentation of these peptides have been reported 
to highly affect the overall cellular functions [38, 39] such as cell proliferation, gene expression and 
differentiation [30]. This effect can be attributed to the variation in adhesion strength between the cells 
and the substrate. Moreover, spacer sequences (commonly polyethylene glycol) must be long enough, 
depending of the exposed signal in order)   [40] to prevent steric hindrance and to allow for maximal 
receptor binding, but they must also be short enough to allow for synergistic interactions. The presence of 
spacers allows for the peptide to present to the cell in a more stable conformation and effectively interact 
with several receptors [41]. To avoid this limitation, some researchers have explored functionalization 
using recombinant fragments of native ECM proteins to maintain the native folding of the protein, to 
retain the same binding motif conformation and orientation and also to inhibit antigenicity. 
 
1.4.2. Growth factors 
Cellular functions are not solely controllable by promoting adhesion and direct interaction with integrins 
and other cell surface receptors. The induction of a specific growth factor’s response is crucial to 
effectively modulating cell activity.  Biodegradable coatings that locally release incorporated growth 
factors (i.e. Bone Morphogenic Protein-2 (BMP-2), IGF and TGF-β) have been successfully tested to 
stimulate fracture healing and to improve biomaterial performance [42]. However, emerging approaches 
have focused on controlling growth factor release kinetics in order to decrease the effective dose and 
Figure 1.1 – Schematic of the interaction between the extra 
cellular matrix and cells. 
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potential side effects [43]. Sponges [44], hydrogels [45], pastes [46, 47], putties, particulates and various 
micro- and nano- carriers [45] have been used to successfully deliver growth factors over long timescales. 
A more sophisticated approach is to exploit the potential of the ECM to regulate the release and functions 
of growth factors. Artificial ECMs have been developed by functionalizing collagen matrices with 
glycosamminoglycans (GAGs) and proteoglycans (PGs) [48] to produce a material able to recreate the in 
vivo environment.  
 
1.4.3. Molecules and artificial ECM: new players in immune-modulation  
In tissue engineering biomaterial implantation is usually accompanied by the injury provoked by the 
surgical procedure. Tissue or organ injury initiates an inflammatory response to the biomaterial starting 
with the formation of a provisional matrix [31, 49]. The ability of the immune system to correctly resolve 
the entire wound healing phases is important in determining the final success of the implanted 
biomaterials. As such, another crucial role of the ECM is regulating and integrating different and 
consecutive key processes during the wound healing: hemostasis, inflammation, proliferation and 
remodeling of the injured tissue.  
During hemostasis, platelets are activated by signals from damaged vascular tissue that induce clot 
formation. In this phase, there is a formation of a provisional matrix consisting of fibrin and entrapped 
erythrocytes [49]. Additionally, the secretion of chemokines initiates the recruitment of neutrophils, 
macrophages, fibroblasts, and resident cells [50]. During the early phases of inflammation, neutrophils are 
the first cells to be recruited and to arrive at the wound site. They start to phagocyte all the foreign 
material, bacteria, or dead cells around the wound site while secreting biomolecular cytokines to recruit 
macrophages. Pro-inflammatory macrophages (M1 phenotype) secrete cytokines and chemokines that 
promote the further recruitment of other leukocytes to the site of injury [51]. Macrophages then change to 
a more reparative phenotype (M2 phenotype, also called “alternatively activated”) in order to remove 
apoptotic neutrophils, thus leading to the resolution of the inflammatory phase [50, 52], and, ultimately, 
to the remodeling phase. The proliferation process involves cellular proliferation, angiogenesis, and new 
ECM deposition. These are largely mediated via cytokines secreted by macrophages, T lymphocytes, and 
other cells within the wound site [52]. Finally the remodeling phase is characterized by the degradation 
and remodeling of the newly deposited ECM, which is mediated by metalloproteinase (MMP) and tissue 
inhibitor of metalloproteinase (TIMP), This generally results in scar tissue formation or maturation [50-
53]. 
In particular, the foreign body reaction (FBR), composed of macrophages and foreign body giant cells, 
has been shown to play a critical role in the successful performance of the artificial ECM and mediates 
the rejection of the implant [31]. For this particular event the biomaterials surface plays the most 
important role. In fact, in the very early process of implantation, blood/material interactions occur with 
protein adsorption to the biomaterial surface and development of a blood-based transient provisional 
matrix that forms on and around the biomaterial. On the contrary, the appropriate functionalization of the 
biomaterials to be implanted can help in inducing a newly described mechanism that switched 
macrophages from a detrimental (inflammatory, M1) to a beneficial (regenerative, M2) phenotype [32, 
33]. This process, known as “macrophage polarization” can thereby influence macrophages consequent 
behavior, such as phagocytosis and cytokines secretion. Significant efforts have focused on modifying 
material properties using various anti-inflammatory polymeric surface coatings to generate more 
biocompatible implants. The specific features of any synthetic biomaterials are able to tune the formation 
of giant cells. These multinucleate macrophages can be found at biomaterial surfaces even years 
following implantation. Recent studies have demonstrated that altering the properties of the bulk materials 
it is possible to influence the preferential polarization of macrophages [54, 55]. Indeed, natural derived 
biomaterials elicit a different immune response due to their native structure and surface, as well as the 
presence of natural ligands that promote constructive tissue remodeling. This anabolic process has been 
directly linked to the ability of material to polarize macrophage phenotypes [56, 57]. This suggests that 
biomaterial design strategies able to control the macrophage phenotype may improve the regenerative 
medicine applications.  
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A better understanding of the context-specific biological mechanisms, which underlie the macrophage 
response and macrophage polarization, is essential for the development of biomimetic strategies for 
appropriate functional tissue remodeling responses.  
Different strategies of coatings of anti-inflammatory molecules have been exploited in order to release 
drugs by passive mechanism [58-60] or by enzymatic secondary reaction [61-63]. As an example of 
passive mechanism, dexamethasone, a synthetic glucocorticoid hormone, has been used as an anti-
inflammatory agent and has been shown to locally reduce the inflammation of the surrounding tissues [64, 
65]. Another example of bio-inspired materials can be demonstrated by coating of superoxide dismutase 
(scavenger enzyme with anti-inflammatory properties) covalently attached to a polyethylene surface to 
reduce neutrophil recruitment [66]. To achieve the desired in vivo response appropriate coatings need to 
be designed.  
Tunable, immune-modulatory materials may be able to actively direct cell behavior and activity 
surrounding the implant, thereby encouraging more desirable interactions.  
 
1.5. Biomimicry of the biochemical gradients occurring in the regenerative process 
Several issues affect the therapeutic efficacy of GFs, including their short protein half-life in vivo, side-
effects caused by the multiple or high doses administered to reach the desirable concentration in the cell, 
and possible denaturation of the protein during manipulation, and these should be carefully considered in 
the design of GF-based therapeutics [67]. Most therapeutic proteins (e.g. GFs, cytokines) that are 
administered in their native form and without any protection are susceptible to biodegradation, resulting 
in insufficient amounts of those proteins at the active site, or resulting in the generation of inactive 
variants [67]. In the search for methods that can overcome these disadvantages, encapsulation of a GF in a 
delivery system has been demonstrated to be very promising for GF-based therapeutics. This technology, 
known as localized delivery, is frequently the only feasible strategy if a locally controlled concentration 
of a GF is necessary, and it has found wide spread use in wound healing and tissue regeneration. 
Nanomedicine has been offering numerous innovative possibilities also in this regenerative strategies 
[68]. However, of the diverse array of particles developed in laboratories, only a few have made their way 
to the clinic [69]. The ideal carrier for tissue engineering applications should be biocompatible, 
biodegradable, present a high surface area to accommodate a high amount of molecules and also 
modifiable to tune the release [67]. Herein, we have been focusing on the advances in molecules and 
protein release to create temporal and spatial patterns of molecules and GFs to mimic the biochemical 
gradients of the natural healing process.  
 
1.6.  Control over growth factor release  
The action of GFs is typically concentration dependent [70]. Thus, GFs release has to be precisely 
controlled. A plethora of nanostructured particulate technologies have been developed, aiming at 
delivering proteins [71], peptides [72], drugs [73], and genetic materials [74], in a controlled fashion in 
the site to be regenerated [68, 75, 76].  
 
1.6.1. Polymeric vectors  
Polymeric materials are frequently used to allow controlled, sustained, and localized delivery of proteins. 
Polymer delivery vehicles allow to control the kinetics and dose of protein release while also protecting 
the protein from degradation until release [68].  
At the end of 1980s it was clear that tissue engineering could benefit of a controlled delivery of GFs and 
the number and complexity of delivery systems tremendously rose [77]. Several delivery systems 
prepared from gelatin and collagen were developed as implants [78]. Another material which has been 
greatly exploited is alginate, to synthesize beads ionically crosslinked [79, 80]. Furthermore, injectable 
gelatin microspheres were developed by the group of Tabata [81, 82]. In mid-1990s, research further 
focused on the design of new delivery systems based on biodegradable microspheres. In particular, 
polylactic acid and poly(lactic-co-glycolic acid) (PLA and PLGA) generated tremendous interest due to 
their excellent biocompatibility as well as the possibility to tailor their biodegradability by varying 
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composition (lactide/glycolide ratio) [83, 84], molecular weight and chemical structure (i.e. capped and 
uncapped end-groups) [77]. In particular, FDA approval of PLGA use in humans led to the availability of 
copolymers characterized by a wide range of in vivo life-times, ranging from 3 weeks to over 1 year [60]. 
Drug microencapsulation within PLGA copolymers, in form of micro- and nanoparticles, was regarded as 
a powerful mean to achieve sustained release for long time-frames and, in the case of labile molecules, 
such as proteins, effectively protect the molecule from in vivo degradation occurring at the administration 
site. Protein encapsulation in PLGA microspheres is a challenging task due to stability issues occurring 
during microsphere-processing, shelf-life and protein release [60]. Techniques to entrap protein in PLGA 
microspheres feature partly competing and partly complementary characteristics [85], and are all joined 
by the common aim of realizing experimental conditions as mild as possible. Fabrication methods 
actively used for physical encapsulation of growth factors include solvent casting and particulate 
leaching, freeze drying, phase separation, melt molding, phase emulsion, in situ polymerization and gas 
foaming [71]. A key issue is minimizing exposure of factors to harsh conditions during processing in 
order to protect the activity of the biomolecules [85].  
Currently, the synthesis of PLGA follows well established protocols that provide the flexibility of 
producing PLGA particles with various size, shape, surface chemistry and also nanostructured enclosures 
[86, 87]. Moreover, PLGA is hydro-soluble, and not immunogenic. Some of this carriers have also the 
unique ability to co-encapsulate multiple molecules and control the release of each agent in a temporal 
fashion, or to trigger the release by responding to environmental changes, such as pH, temperature, light, 
and mechanical stress [6]. However, the preservation of proteins’ stability during particles’ fabrication 
still remains a concern.  
 
1.6.2. Silica-based vectors 
A successful approach to preserve protein stability and at the same time allowing for an efficient protein 
loading has been proposed by De Rosa et al., who tested mesoporous silica particles (pSi) for high 
loading of proteins, and an agarose coating to further increase protein stability in the carrier [88]. pSi have 
been widely used for tissue engineering and drug delivery in virtue of its biodegradable and biocompat-
ible nature [89, 90]. For therapeutic delivery, pSi has been administered orally [91], intravenously [92], or 
injected percutaneously and intraperitonealy in humans for brachytherapy without notable side effects 
[93]. A wide variety of therapeutic and imaging agents have been successfully loaded into and released 
from pSi particles including antibiotics [94], hormones [95], proteins [96], liposomes [17] and carbon 
nanotubes [97], showing the great versatility of this material as a delivery system. As a scaffold, pSi is 
suitable for directing the growth of neuronal cells [98] and for stimulating mineralization in bone tissue 
engineering [99, 100]. pSi structure and the idea of using it in nanotechnology applications came 
mimicking the structure of diatoms shell, which is characterized by a regular structure and high surface 
area [101, 102]. The size and shape as well as the porosity and pore size of the pSi particles can be 
engineered and tightly controlled during manufacturing [103], in order to provide a material with constant 
and uniform physical features at the micro- and nanometer scale and to control degradation time and 
kinetics as well as biodistribution and bioaccumulation [104, 105]. Additionally, their surface can be 
functionalized to be linked to scaffold or to control the release kinetics of the payload [88, 106]. Bovine 
serum albumin (BSA) and BMP-2 were also loaded into pSi particles to examine in vitro release kinetics 
of the proteins [106]. Furthermore, pSi itself has a regenerative potential: it is osteoinductive (it has the 
capacity to stimulate primitive stem cells or immature bone cells to grow and mature, forming healthy 
bone tissue) and also osteoconductive (it can serve as a scaffold on which bone cells can attach and grow 
so that the bone healing response is lead towards the graft site) [107]. The osteoconductivity of pSi can be 
controlled by altering the interfacial chemistry and micro-structure of the pores. The range of pore size 
and structure affords the identification of the preferred morphology for osteoblast adhesion, growth, 
protein matrix synthesis and mineralization.  
Several coating strategies were also developed to avoid the burst release of proteins from the pores and to 
achieve a sustained and tunable release over the course of weeks [106, 108].  
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1.6.3. Composite vectors 
The importance of GFs in the regulation of various cell processes, and the need to carefully regulate GF 
presentation, suggests that sophisticated approaches to their delivery will be crucial to affect desired 
cellular responses [109]. As discussed above, PLGA has been extensively used for its several advantages. 
However, PLGA release rates (as well as for pSi) are characterized by an initial burst release that partially 
hinders the ability to control the timed delivery of payloads [110, 111]. Also, the by-products of PLGA 
degradation decrease the pH of the surrounding micro-environment resulting in the inherent 
destabilization or denaturation of the protein payload [112]. In order to address these issues, Fan et al. 
introduced a composite delivery platform composed of a pSi core encapsulated in a PLGA shell (PLGA-
pSi) [106]. The authors demonstrated that silicon nanoparticles had no immunogenic or toxic effects and 
that both the PLGA and the pSi component were fully biodegradable[113]. The use of pSi in combination 
with PLGA enabled the double controlled delivery of molecules, resulting in the extension of the 
therapeutic window and prevented the acidification of the system during the degradation process resulting 
in better stabilization of the payload and in a better in vivo therapeutic outcome [106, 114]. Compared 
with pSi, a larger quantity of biomolecules could be loaded and stored into the PLGA-pSi composite 
microparticles.  
Recently, Bhattacharyya et al. also proposed a PEG-coated mesoporous silica nanoparticles (MSN) with 
incorporated trypsin inhibitor (a model protein molecule for growth factors) [115]. Due to the goal of 
incorporating large protein molecules the pore size of the as-synthesized MSNs was expanded by a 
hydrothermal treatment prior to payload incorporation. In vitro release from the MSNs without the thin 
polymer film shows an initial burst followed by continuous release. In the case of polymer-coated MSNs 
the initial burst release was completely suppressed and approximate zero order release was achieved for 4 
weeks. 
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CHAPTER 2 
 
 
ANALITICAL METHODS 
 
 
 
 
2.1.Microscopy 
 
2.1.1. Scanning electron microscopy (SEM)  
The scanning electron microscope (SEM) is a type of electron microscope that creates various images by focusing 
a high energy beam of electrons onto the surface of a sample and detecting signals from the interaction of the 
incident electrons with the sample's surface [1]. The type of signals gathered in a SEM vary and can include 
secondary electrons, characteristic x-rays, and back scattered electrons (Fig. 2.1) [2]. In a SEM, these signals 
come not only from the primary beam impinging upon the sample, but from other interactions within the sample 
near the surface. The SEM is capable of producing high-resolution images of a sample surface in its primary use 
mode, secondary electron imaging. Due to the manner in which this image is created, SEM images have great 
depth of field yielding a characteristic three-dimensional appearance 
useful for understanding the surface structure of a sample. This 
great depth of field and the wide range of magnifications are the 
most familiar imaging mode for specimens in the SEM. 
Characteristic x-rays are emitted when the primary beam causes the 
ejection of inner shell electrons from the sample and are used to tell 
the elemental composition of the sample. The back-scattered 
electrons emitted from the sample may be used alone to form an 
image or in conjunction with the characteristic x-rays as atomic 
number contrast clues to the elemental composition of the sample. 
In a typical SEM, thermo-ionic electrons are emitted from a 
tungsten cathode and are accelerated towards an anode (Fig. 2.2) 
[3]. Tungsten is used because it has the highest melting point and 
lowest vapour pressure of all metals, thereby allowing it to be 
heated for electron emission. The electron beam, which typically 
has an energy ranging from a few hundred eV to 100 keV, is 
focused by one or two condenser lenses into a beam with a very fine 
focal spot sized 0.4 nm to 5 nm. The beam passes through pairs of 
scanning coils or pairs of deflector plates in the electron optical column, typically in the objective lens, which 
deflect the beam horizontally and vertically so that it scans in a raster fashion over a rectangular area of the 
sample surface. When the primary electron beam interacts with the sample, the electrons lose energy by repeated 
scattering and absorption within a teardrop-shaped volume of the specimen known as the interaction volume, 
which extends from less than 100 nm to around 5 μm into the surface. The size of the interaction volume depends 
on the electrons' landing energy, the atomic number of the specimen and the specimen's density. The energy 
exchange between the electron beam and the sample results in the emission of electrons and electromagnetic 
radiation, which can be detected to produce an image, as described below. 
 
 
 
 
 
Figure 2.1 - Signals produced by the interaction of 
the electron beam with the sample. 
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2.1.1.1. Detection of secondary electrons 
The most common imaging mode monitors low energy (<50 eV) secondary electrons. Due to their low energy, 
these electrons originate within a few nanometers from the surface. The electrons are detected by a scintillator-
photomultiplier device and the resulting signal is rendered into a two-dimensional intensity distribution that can 
be viewed and saved as a digital image. This process relies on a raster-scanned primary beam. The brightness of 
the signal depends on the number of secondary electrons 
reaching the detector. If the beam enters the sample 
perpendicular to the surface, then the activated region is 
uniform about the axis of the beam and a certain number of 
electrons "escape" from within the sample. As the angle of 
incidence increases, the "escape" distance of one side of the 
beam will decrease, and more secondary electrons will be 
emitted. Thus steep surfaces and edges tend to be brighter than 
flat surfaces, which results in images with a well-defined, three-
dimensional appearance. Using this technique, resolutions less 
than 100 nm are possible. 
 
2.1.1.2. Resolution of the SEM 
The spatial resolution of the SEM depends on the size of the 
electron spot, which in turn depends on both the wavelength of 
the electrons and the magnetic electron-optical system which 
produces the scanning beam. The resolution is also limited by 
the size of the interaction volume, or the extent to which the 
material interacts with the electron beam. The spot size and the 
interaction volume both might be large compared to the 
distances between atoms, so the resolution of the SEM is not 
high enough to image individual atoms, as is possible in the 
shorter wavelength (i.e. higher energy) transmission electron 
microscope (TEM). The SEM has compensating advantages, 
though, including the ability to image a comparatively large 
area of the specimen; the ability to image bulk materials (not 
just thin films or foils); and the variety of analytical modes 
available for measuring the composition and nature of the specimen. The equipment employed in this study was a 
FEI Quanta 400 ESEM FEG, FEI, Hillsboro, OR.   
 
 
2.1.2. Fluorescence microscopy 
 
2.1.2.1. Principles of Fluorescence 
The technique of fluorescence microscopy has become an essential tool in biology and the biomedical sciences, as 
well as in materials science due to attributes that are not readily available in other contrast modes with traditional 
optical microscopy. The application of an array of fluorochromes has made it possible to identify cells and sub-
microscopic cellular components with a high degree of specificity amid non-fluorescing material. In fact, the 
fluorescence microscope is capable of revealing the presence of a single molecule. Through the use of multiple 
fluorescence labeling and different probes can simultaneously identify several target molecules simultaneously 
[4].  
 
2.1.2.2. Excitation and emission 
Fluorescence microscopy requires that the objects of interest fluoresce, thus requires the use of fluorochromes, 
that are essentially dyes, which accept light energy (e.g. from a laser) at a given wavelength and re-emit it at a 
Figure 2.2 - Scheme of a Scanning Electron Microscope. 
18 
 
longer wavelength. These two processes are called excitation and emission. Fluorescence is the emission of light 
that occurs within nanoseconds after the absorption of light that is typically of shorter wavelength.  
In details, light is a form of electromagnetic energy that travels in waves. These waves have both frequency and 
length, the latter of which determines the color of light. The light that can be visualized by the human eye 
represents a narrow wavelength band (380–700 nm) between ultraviolet (UV) and infrared (IR) radiation. When 
light is absorbed by a fluorochrome, its electrons become excited and move from a resting state to a maximal 
energy level called the excited electronic singlet state. The amount of energy required will differ for each 
fluorochrome. This state only lasts for 1–10 nanoseconds because the fluorochrome undergoes internal 
conformational change and, in doing so, releases some of the absorbed energy as heat. The electrons subsequently 
fall to a lower, more stable, energy level called the relaxed electronic singlet state. As electrons steadily move 
back from here to their ground state they release the remaining energy (emission) as fluorescence. The difference 
between the exciting and emitted wavelengths, known as the Stokes shift, is the critical property that makes 
fluorescence so powerful [4, 5].  
 
2.1.2.3. Fluorophores 
Molecules that are used by virtue of their fluorescent properties are called fluorophores. Fluorochromes are stains 
that attach themselves to visible or sub-visible structures, are often highly specific in their attachment targeting. 
The outermost electron orbitals in the fluorophore molecule determine both its efficiency as a fluorescent 
compound and the wavelengths of absorption and emission. When fluorescent compounds in their so-called 
‘ground state’ absorb light energy (photons), alterations in the electronic, vibrational and rotational states of the 
molecule can occur. The absorbed energy sometimes moves an electron into a different orbital that is on average 
farther away from the nucleus. Whereas many organic substances have intrinsic fluorescence (autofluorescence), 
and a few are useful for specific labeling of components in biological systems, the typical approach to 
fluorescence microscopy is to take advantage of synthesized compounds that have some degree of conjugated 
double bonds. Such compounds often have ring structures (aromatic molecules) with pi bonds that easily 
distribute outer orbital electrons over a wide area. In general, the more conjugated bonds in the molecule, the 
lower the excited energy requirement and the longer the wavelength (redder) the exciting light can be. The 
emitted light is shifted in the same direction [5].  
 
2.1.2.4. Fluorescence microscope 
The preferred illumination approach in modern fluorescence microscopes is epi-illumination. In this configuration 
the microscope objective not only has the familiar role of imaging and magnifying the specimen, but also serves 
as the condenser that illuminates it. The advantage of this approach over transmission, fluorescence microscopes 
(in which the exciting light comes through the condenser and the emission is collected by the objective) is that 
whereas the excitation of the fluorophore is equivalent in both epi- and transmitted microscopes, only the small 
percentage of the exciting light that is reflected off the sample needs to be blocked in the return light path in the 
epi-illumination mode. The main technical hurdle with this approach is that the exciting light and fluorescence 
emission overlap in the light path requiring a special kind of beam splitter, a dichroic mirror, to separate the 
excitation from the emission. The dichroic beam splitter mirror is designed to be used in light paths at 45°. In 
ordinary fluorescence microscopes, the dichroic reflects shorter wavelength light originating from the light source 
and transmits the longer wavelengths of the emitted fluorescence. Each dichroic is designed to have a transition 
from reflection to transmission that resides between the excitation and emission peaks of the fluorophore it is 
designed to be used with [5, 6].  
There are several different strategies for fluorescence illumination. Traditionally the intensities needed for 
comfortable viewing by eye or rapid camera exposure come from arc lamps. Mercury and xenon arc lamps are 
expensive, potentially dangerous, and require special lamp houses and power supplies. These two types of arc 
lamps differ in several important ways. Depending on your requirements xenon or mercury is the better choice. 
Xenon has the advantage of being relatively even in the coverage of wavelengths throughout the UV, visible and 
near infrared. Mercury, however, is a spectrally peaky light source with several extremely intense lines [5]. An 
Eclipse Ti-U was used in this PhD project (NIKON).  
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2.1.2.5. Confocal laser microscope 
Confocal microscopy offers several advantages over conventional optical microscopy, including shallow depth of 
field, elimination of out-of-focus glare, and the ability to collect serial optical sections from thick specimens. In 
the biomedical sciences, a major application of confocal microscopy involves imaging either fixed or living cells 
and tissues that have usually been labeled with one or more fluorescent probes. 
Confocal imaging involves serially scanning the specimen to create computer-generated optical sections down to 
250 nm thickness using visible light. These optical sections may be stacked to provide a 3-D digital reconstruction 
of the specimen. Since the resolution possible in the laser scanning confocal microscope (LSCM) is somewhat 
better than in the conventional widefield optical microscope, but still considerably less than that of the 
transmission electron microscope, it has in some ways bridged the gap between the two more commonly used 
techniques [7]. 
In a conventional widefield microscope, the entire specimen is bathed in light from a mercury or xenon source, 
and the image can be viewed directly by eye or projected directly onto an image capture device or photographic 
film. In contrast, the method of image formation in a confocal microscope is fundamentally different. The 
illumination is achieved by scanning one or more focused beams of light, usually from a laser, across the 
specimen. The images produced by scanning the specimen in this way are called optical sections. This 
terminology refers to the noninvasive method by which the instrument collects images, using focused light rather 
than physical means to section the specimen. The confocal approach has facilitated much more useful imaging of 
living specimens, enabled the automated collection of three-dimensional (z-series) data, and improved the images 
obtained of specimens using multiple labeling [7].  
The basic optics of the optical microscope have remained fundamentally unchanged for decades because the final 
resolution achieved by the instrument is governed by the wavelength of light, the objective lens, and the 
properties of the specimen itself. The dyes used to add contrast to specimens, and other technology associated 
with the methods of optical microscopy, have improved significantly over the past 20 years.  
There are currently two alternative methods to confocal microscopy that are in use for producing optical sections: 
deconvolution and multiphoton imaging. They differ technically, but like confocal methods, are based on the 
conventional optical microscope. Deconvolution uses computer-based algorithms to calculate and remove out-of-
focus information from fluorescence images. Due to more efficient algorithms and much faster mini computers, 
this technique has become a practical option for imaging. Multiphoton microscopy uses the same scanning system 
as the c, but does not require the pinhole aperture at the detector. The pinhole is unnecessary because the laser 
excites the fluorochrome label only at the point of focus, eliminating the out-of-focus emission. An additional 
benefit in the imaging of living tissues is that photobleaching is reduced in the specimen due to the reduced 
energy absorbed from the laser beam. The conventional optical microscope forms the basis around which the 
LSCM is built. Instead of a tungsten or mercury lamp, a laser is used as a light source, and is combined with a 
sensitive photomultiplier tube (PMT) detector, and a computer to control the scanning mirrors or other scanning 
devices and to facilitate the collection and display of images. Following acquisition the images are stored on 
digital media and may be analyzed by any of the numerous image processing software packages available using 
either the microscope system computer or a second computer [7]. In this study a Nikon A1 confocal laser 
microscope was used (NIKON).  
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2.2. Physical-chemical analysis  
 
2.2.1. Fourier transform infrared spectroscopy (FTIR)  
FTIR is the subset of spectroscopy that deals with the infrared region of the electromagnetic spectrum.  
The infrared portion of the electromagnetic spectrum is divided into three regions; the near-, mid- and far- 
infrared, named for their relation to the visible spectrum. The far-infrared, approximately 400-10 cm-1 (1000–30 
μm), lying adjacent to the microwave region, has low energy and may be used for rotational spectroscopy. The 
mid-infrared, approximately 4000-400 cm-1 (30–1.4 μm) may be used to study the fundamental vibrations and 
associated rotational-vibrational structure. The higher energy near-IR, approximately 14000-4000 cm-1 (1.4–0.8 
μm) can excite overtone or harmonic vibrations.  
Infrared spectroscopy exploits the fact 
that molecules have specific frequencies 
at which they rotate or vibrate 
corresponding to discrete energy levels 
(Fig. 2.3) [8]. These resonant frequencies 
are determined by the shape of the 
molecular potential energy surfaces the 
masses of the atoms and, by the coupling 
of vibrational and electronic interactions 
in the molecule.  
Thus, the resonant frequencies can be in 
a first approach related to the strength of 
the bond, and the mass of the atoms at 
either end of it. Thus, the frequency of 
the vibrations can be associated with a 
particular bond type and can be used for 
the characterization of very complex 
mixtures.  
The infrared spectra of a sample is collected by passing a beam of infrared light through the sample. Examination 
of the transmitted light reveals how much energy was absorbed at each wavelength (see Fig. 2.4). 
This can be done with a monochromatic beam, which changes in wavelength over time, or by using a Fourier 
transform instrument to measure all wavelengths at once. From this, a transmittance or absorbance spectrum can 
be produced, showing at which IR wavelengths the sample absorbs. Analysis of these absorption characteristics 
reveals details about the molecular structure of the sample. The method employed for sample preparation is to 
grind a quantity of the sample with potassium bromide finely (to remove scattering effects from large crystals), 
which is used also as a reference. This powder mixture is then crushed in a mechanical die press to form a 
translucent pellet through which the beam of the spectrometer can pass.  
A reference is used for two reasons:  
• This prevents fluctuations in the output of the source affecting the data;  
• This allows the effects of the solvent to be cancelled out (the reference is usually pure solvent).  
The equipment employed in the present work was a Thermo Nicolet-Avatar 320 FT-IR. 
 
2.2.2. Inductively coupled plasma (ICP) 
Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) is a type of emission spectroscopy that 
uses a plasma (e.g. inductively coupled plasma) to produce excited atoms that emit electromagnetic radiation at a 
wavelength characteristic of a particular element. The intensity of the radiation is proportional to the 
concentration of the element, which is obtained through a previous calibration obtained with opportune standard 
solutions. An inductively coupled plasma (ICP) for spectrometry is sustained in a torch that consists of three 
concentric tubes, usually made of quartz. The end of this torch is placed inside an induction coil supplied with a 
radio-frequency electric current. A flow of argon gas is introduced between the two outermost tubes of the torch 
and an electrical spark is applied for a short time to introduce free electrons into the gas stream. These electrons 
Figure 2.3 - Possible vibrations detected by infrared spectroscopy.  
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interact with the radio-frequency magnetic field of the induction coil and are accelerated first in one direction, 
then the other, as the field changes at high frequency. The accelerated electrons collide with argon atoms, and 
sometimes a collision causes an argon atom to 
part with one of its electrons. The released 
electron is in turn accelerated by the rapidly-
changing magnetic field. The process continues 
until the rate of release of new electrons in 
collisions is balanced by the rate of 
recombination of electrons with argon ions 
(atoms that have lost an electron). This produces 
a ‘fireball’ that consists mostly of argon atoms 
with a rather small fraction of free electrons and 
argon ions. The samples to be analyzed are firstly 
solubilized and then introduced into the hot 
region through an atomizer. The temperature of 
the plasma is very high, of the order of 10.000 K, 
 
2.2.3. Thermo-gravimetric Analysis  (TGA) 
Thermogravimetric Analysis or TGA is a type of testing that is performed on samples to determine changes in 
weight in relation to change in temperature. Such analysis relies on a high degree of precision in three 
measurements: weight, temperature, and temperature change. As many weight loss curves look similar, the weight 
loss curve may require transformation before results may be interpreted. A derivative weight loss curve can be 
used to tell the point at which weight loss is most apparent.  
The analyzer usually consists of a high-precision balance with a pan loaded with the sample. The sample is placed 
in a small electrically heated oven with a thermocouple to accurately measure the temperature. The atmosphere 
may be purged with an inert gas to prevent oxidation or other undesired reactions. A computer is used to control 
the instrument. Analysis is carried out by raising the temperature gradually and plotting weight against 
temperature. After the data is obtained, curve smoothing and other operations may be done such as to find the 
exact points of inflection.  A Q600 instrument was used in this study (TA instruments).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 - Scheme of equipment for infrared spectroscopy. 
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2.3.Biomolecular techniques  
 
2.3.1. Principles of the Flow Cytometry 
One of the fundamentals of flow cytometry is the ability to measure the properties of individual particles. When a 
sample in solution is injected into a flow cytometer, the particles are randomly distributed in three-dimensional 
space. The sample must therefore be ordered into a stream of single particles that can be interrogated by the 
detection system of the machine. This process is managed by the fluidics system. Essentially, the fluidics system 
consists of a central channel/core through which the sample is injected, enclosed by an outer sheath that contains 
faster flowing fluid. As the sheath fluid moves, it creates a massive drag effect on the narrowing central chamber. 
This alters the velocity of the central fluid whose flow front becomes parabolic with greatest velocity at its center 
and zero velocity at the wall. The effect creates a single file of particles and is called hydrodynamic focusing. 
Under optimal conditions (laminar flow) the fluid in the central chamber will not mix with the sheath fluid. 
After hydrodynamic focusing, each particle passes through one or more beams of light. Light scattering or 
fluorescence emission (if the particle is labeled with a fluorochrome) provides information about the particle’s 
properties. The laser and the arc lamp are the most commonly used light sources in modern flow cytometry. 
Lasers produce a single wavelength of light (a laser line) at one or more discreet frequencies (coherent light). Arc 
lamps tend to be less expensive than lasers and exploit the color emissions of an ignited gas within a sealed tube. 
However, this produces unstable incoherent light of a mixture of wavelengths, which needs subsequent optical 
filtering. Light that is scattered in the forward direction, typically up to 20° offset from the laser beam’s axis, is 
collected by a lens known as the forward scatter channel (FSC). The FSC intensity roughly equates to the 
particle‟s size and can also be used to distinguish between cellular debris and living cells. Light measured 
approximately at a 90° angle to the excitation line is called side scatter. The side scatter channel (SSC) provides 
information about the granular content within a particle. Both FSC and SSC are unique for every particle, and a 
combination of the two may be used to differentiate different cell types in a heterogeneous sample. 
Fluorescence measurements taken at different wavelengths can provide quantitative and qualitative data about 
fluorochrome-labeled cell surface receptors or intracellular molecules such as DNA and cytokines. Flow 
cytometers use separate fluorescence (FL-) channels to detect light emitted. The number of detectors will vary 
according to the machine and its manufacturer. Detectors are either silicon photodiodes or photomultiplier tubes 
(PMTs). 
The specificity of detection is controlled by optical filters, which block certain wavelengths while transmitting 
(passing) others. There are three major filter types. Long pass filters allow through light above a cut-off 
wavelength, short pass permit light below a cut-off wavelength and band pass transmit light within a specified 
narrow range of wavelengths (termed a band width). When a filter is placed at a 45° angle to the oncoming light it 
becomes a dichroic filter/mirror. As the name suggests, this type of filter performs two functions, first, to pass 
specified wavelengths in the forward direction and, second, to deflect blocked light at a 90° angle. To detect 
multiple signals simultaneously, the precise choice and order of optical filters will be an important consideration. 
When light hits a photodetector a small current (a few microamperes) is generated. Its associated voltage has an 
amplitude proportional to the total number of light photons received by the detector. This voltage is then 
amplified by a series of linear or logarithmic amplifiers, and by analog to digital convertors (ADCs), into 
electrical signals large enough (5–10 volts) to be plotted graphically. Log amplification is normally used for 
fluorescence studies because it expands weak signals and compresses strong signals, resulting in a distribution 
that is easy to display on a histogram. Linear scaling is preferable where there is not such a broad range of signals 
e.g. in DNA analysis. The measurement from each detector is referred to as a parameter e.g. forward scatter, side 
scatter or fluorescence. The data acquired in each parameter are known as the events and refer to the number of 
cells displaying the physical feature or marker of interest. The speed of flow sorting depends on several factors 
including particle size and the rate of droplet formation. A typical nozzle is between 50–70 μM in diameter and, 
depending on the jet velocity from it, can produce 30,000–100,000 droplets per second, which is ideal for accurate 
sorting. Higher jet velocities risk the nozzle becoming blocked and will also decrease the purity of the 
preparation. A BD LSRFortessa™ flow cytometer was used in this study.  
2.3.2. RNA extraction and quantitative polymerase chain reaction (RT-PCR) 
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To determine the nature of the cells used in this study at a molecular level, a set of Reverse Transcription-
Polymerase Chain Reaction (RT-PCR) analysis was performed. Total RNA was isolated from cells using 
TRIZOL® Reagent (Invitrogen, Carlsbad, CA), according to the protocol indicated by the manufacturer. RNA 
concentration and purity were measured using a NanoDrop Spectrophotometer (NanoDrop ND1000, Wilmington, 
DE, USA). To avoid false-positive results attributable to the amplification of contaminating genomic DNA, total 
RNA was treated with DNase (Sigma). For the evaluation of stemness, RNA was isolated from AECs at passages 
P0, P1, P3 and P5. In order to examine the differentiation potential, RNA was extracted from both cells subjected 
to differentiation induction and control cells (negative controls). Moreover, total RNA was isolated form adult 
tissues (bone tissue, adipose tissue and spinal cord) and was used as positive controls for the expression of the 
differentiation markers. Retrotranscription is a reaction that allows obtaining a DNA strand (cDNA) 
complementary to the RNA isolated. For this purpose, four elements are needed: RNA of interest, 
deoxyribonucleotides (dNTPs) as building blocks of cDNA, an oligonucleotide able to pair with a portion of the 
RNA strand and the enzyme retrotranscriptase, able to synthesize DNA starting from an RNA strand. 
Complementary DNA (cDNA) was synthesized from 500 ng of total RNA using the iScript retrotranscription kit 
(Bio-Rad Laboratories, Hercules, CA) at the following conditions: 
- 25 ° C for 5 minutes; 
- 42 ° C for 30 minutes; 
- 85 ° C for 5 minutes. 
The PCR reaction allows amplifying specific sequences of the cDNA obtained through retrotranscription. The 
efficiency of this reaction depends on several aspects, such as the ability of primers – forward and reverse – to 
specifically recognise the binding site on cDNA, the annealing temperature of primers and the concentration of 
MgCl2. The cDNA double strand is subjected to denaturation at high temperatures (95°C). When the two strands 
are separate, primers must pair with them in a specific and selective way, searching for their complementary 
sequence on cDNA. This phase is known as annealing and it can be efficient, stable and specific only at a specific 
temperature value (the annealing temperature), which depends only on the primer sequence. When temperature is 
too low, non-specific interactions can be favoured, generating unspecific results. Moreover, it is important to 
evaluate the buffer molarity and the MgCl2 concentration: in effect, too high concentrations of MgCl2 bestow a 
certain viscosity to the sample, causing non-specific results. On the contrary, a too low concentration reduces the 
efficiency of the reaction. Finally, MgCl2 concentration has to be chosen in regard to the concentrations of 
template, dNTPs and primers; all these elements possess phosphate groups, which interact with Mg+ ions, making 
them less available for the enzyme. PCR reaction was performed using the “Taq DNA Polymerase recombinant” 
commercial kit (Invitrogen Life Technologies, 10342-053). The enzyme is purified from a modified Escherichia 
coli strain able to express the gene of Thermus aquaticus DNA polymerase. This DNA polymerase is 
thermostable, so it can synthesize DNA at high temperatures. The amplification reaction consists of the repetition 
of three steps, for a number of cycles which depends on the target sequence and on the exponential amplification: 
Denaturation of the double helix; 2) Annealing of the primers to the cDNA strand; 3) Extension of the double 
helix by the DNA polymerase activity. All the amplification reactions were performed using a T1 Thermocycler 
(Biometra). The PCR reaction was performed in a reaction mix (20 l) composed of: (i) 10x PCR Buffer: 2 l; (ii) 
25 mM MgCl2: 1.6 l; (iii) 10 mM Deoxynucleotide Mix: 0.4 l; (iv) 10 M Forward Primer: 0.8 l; (v) 10 M 
Reverse Primer: 0.8 l; (vi) Taq DNA Polymerase: 0.2 l; (vii) cDNA: 1 l; (viii) Water: 13.2 l. 
The conditions of the amplification reaction were: 
- Initial denaturation: 94°C for 2 minutes; 
- Denaturation: 94°C for 30 seconds; 
- Annealing: X°C (temperature depending on the melting temperature of primers) for 30 seconds 
- Extension: 72°C for 30 seconds 
- Final elongation: 72°C for 10 minutes 
Denaturation, annealing and extension steps were repeated 32 times. 
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 CHAPTER 3 
 
 
COMPOSITE NANOSTRUCTURED 
CARRIERS FOR BIOACTIVE PROTEINS 
 
 
 
 
3.1. Introduction 
 
Nanomedicine represents a powerful tool to treat a variety of diseases and recently has become a primary strategy 
in different applications of tissue engineering [1].  In regenerative medicine, it has become clear that bioactive 
molecules, such as growth factors (GF) and cytokines, play the crucial role in orchestrating tissue regeneration 
[2]. Such process is led by both the cells of the immune systems (e.g. macrophages) [3] and progenitor ones (e.g. 
mesenchymal stem cells) [4], and have been all exploited as therapeutic targets [5]. To deliver the bioactive 
molecules at the proper time and for the right window of time is necessary to trigger the different stages of the 
regeneration in a temporally controlled fashion [6]. This ensures the right consecution of cell functions necessary 
to start the healing process (e.g. cell migration, growth, differentiation) [7]. The ideal delivery system should be 
fully tunable, to allow the design of virtually infinite possible release kinetics. Furthermore, it should allow for the 
encapsulation of high amount of GF, while preserving their functionality during fabrication.  Although a plethora 
of carriers for the release of bioactive molecules have been proposed over the past decade, none of these platforms 
displayed neither the ideal zero-order release kinetic [8, 9], nor the ability to confine the payload in the target 
defect for the necessary period of time to allow regeneration [10]. The initial burst release represents a limiting 
factor in the clinical use of carriers for the release of therapeutic molecules, and unfortunately characterizes most 
of the currently available delivery systems [11]. In fact, this does not allow for the control over the daily dose of 
molecule to be released and it has been shown to cause major side effects [11]. A notorious controversy spurred 
over the release of GF in tissue engineering applications, when Medtronic developed INFUSE®, a collagen 
sponge impregnated with a solution of recombinant human Bone Morphogenic Protein-2 for bone augmentation. 
Although the market leader for years, this product has been associated with several disruptive patients’ 
complications (e.g. osteolysis, heterotopic ossification and even cancer) [12, 13]. Thus, the ideal carrier should 
concurrently confine and retain the biomolecules over time, to preserve the physiology of the surrounding tissues.  
Poly(lactic-co-glycolic acid) (PLGA) has been proven a material of election for the  fabrication of delivery 
systems, such as microspheres, due to its versatile properties [14-16]. It is approved by Food and Drug 
Administration and European Medicines Agency for applications of drug delivery due to its biodegradability, 
biocompatibility and as it also preserves the GF from degradation. Nano-structured porous silicon particles (pSi) 
have been widely used in the drug delivery field [17], for a multitude of applications, ranging from cancer therapy 
to tissue engineering, where they revealed to be also osteoconductive [18, 19]. The main peculiarities of pSi 
particles is that size, shape, porosity and pore size can be finely tailored during manufacturing [20]. The ability of 
customizing the structure of the particles allows controlling their biodistribution, bioaccumulation, degradation 
time and also the kinetics. A further degree of control can be done on the particles surface: it can in fact be 
functionalized to include various drugs and control cellular uptake [21]. The highly porous and interconnected 
structure of the pSi particles is suitable to load not only small molecules but also proteins and larger payloads. pSi 
have been efficiently incorporated in a wide range of synthetic polymers in the attempt to introduce a further level 
of control on the release of the payload [22, 23].  
Recently, our group developed a PLGA-pSi composite carrier which revealed of great interest in the field of 
tissue engineering as it was demonstrated to allow for the release of high amounts of proteins, while preserving 
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their functionality [24]. Herein, we investigated the influence of both copolymer ratio and size of pSi 
encapsulated, over the release profiles of a reporter protein Bovine Serum Albumine (BSA-FITC).  
 
 
3.2. Materials and methods  
 
3.2.1. Silicon Particles Fabrication and surface modification  
Discoidal pSi particles of 1, 3 and 7 µm in diameter and 400 nm thickness, or hemispherical particles of 3 µm in 
diameter and 600 nm thickness were fabricated by photolithography and electrochemical porosification of 
patterned silicon 
wafers, allowing for 
precise control over 
particle size and shape, 
as previously reported 
[23, 25]. pSi were 
oxidized as extensively 
described elsewhere 
[23, 26]. The surface of 
the pSi particles was 
modified with (3-
Aminopropyl)triethoxys
ilane (APTES) (Sigma–
Aldrich) as previously 
described [23, 25]. pSi 
morphology was evaluated by scanning electron microscopy (SEM). Particles were dispersed in deionized (DI) 
water, and a drop was deposited on metal stubs. Samples were coated with 3 nm of Pt/Pb and imaged at a voltage 
of 7 KV (FEI Quanta 400 ESEM FEG, FEI, Hillsboro, OR). Subsequently, 2 × 10
8
 oxidized particles have been 
suspended and mixed in 1 ml of 4% APTES in Isopropyl alcohol (IPA) solution and 10% DI in IPA. Particles 
have been mixed at 1300 rpm for 2 h with a thermomixer set at 37 ºC and then moved to a vacuum oven for 
annealing at 60 ºC overnight. pSi were labeled with 4',6-diamidino-2-phenylindole (DAPI).  
 
3.2.2. Preparation of PLGA-pSi 
pSi were encapsulated in PLGA particles via double-emulsion method [20]. Several sets of PLGA-pSi composites 
were created, varying pSi content (2.5, 5 and 10 wt%), pSi shape (hemispherical or discoidal), pSi size (1, 3 or 7 
µm). Also, different PLGA coatings have been created, by using the copolymer 50:50, 75:25 or 85:15. 2 × 10
8
 
APTES-modified pSi particles were suspended in 1 ml of different solutions of PLGA (LACTEL), previously 
dissolved in dichloromethane (DCM) (100 mg/ml) (Sigma-Aldrich). PLGA outer shell was fluorescently labelled 
by adding Rhodamine B (Sigma) into the PLGA in DCM solution, at a concentration of 1mg/ml.  The organic 
phase was then emulsified with 3ml of 2.5% poly (vinyl alcohol) (PVA) (Fisher Scientific) (25 mg/ml) at 3000 
rpm for 6 minutes. The emulsion was dropped into 40 ml of a 1% aqueous solution of PVA (10 mg/ml). The 
resulting phase has been stirred overnight to allow DCM evaporation; particles were then washed three times with 
DI water and collected via centrifugation for lyophilization and long term storage.  
 
3.2.3. Characterization of PLGA-pSi 
Full encapsulation of pSi microparticles in the PLGA microspheres was assessed by optical microscopy. The 
effect of pSi content, shape and size, and PLGA copolymer ratio on PLGA-pSi size was investigated by 
measuring the diameter of the microspheres by an automated measuring tool of the software NIS element (Nikon).  
The zeta potential of the silicon particles, prior to encapsulation in the PLGA shell was analyzed using a Zetasizer 
nano ZS (Malvern Instruments Ltd., Southborough, MA), as previously described [27]. APTES-modified pSi and 
the resulting PLGA-pSi microspheres were analyzed by Fourier Transformed Infrared spectroscopy (FTIR). 
Briefly, a KBr pellet was made by mixing KBr to freeze-dried PLGA-pSi. The KBr chip was analyzed by a 
Figure 3.1 - SEM micrographs of hemispherical (A) and discoidal (B) pSi microparticles; scale bar 1 µm. 
Schematic describing the main steps of PLGA-pSi synthesis (C). 
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Nicolet 6700 spectrometer (Thermo Scientific). The pSi content in the composite microspheres was characterized 
by thermogravimetric analysis (TGA), while the thermal properties of PLGA-pSi were evaluated by Differential 
Scanning Calorimetry (DSC) through the Q600 TG-DSC apparatus (TA instruments).  
 
3.2.4. Loading of FITC-BSA into APTES-modified pSi particles and encapsulation in PLGA shell  
In order to load the selected reporter protein, APTES modified pSi particles were suspended in 500 μL of solution 
of FITC-BSA (Sigma–Aldrich) in DI (10 mg/ml). The suspension was incubated in hysiological-like conditions 
(PBS, 37ºC, under mild agitation). Centrifugation at 4000 rpm for 5 minutes allowed the isolation of the particles. 
The collected supernatant has been used to estimate the amount of protein absorbed by mass difference using a 
spectrophotometer 
SpectraMax M2 (Molecular 
Devices) at 493/518 nm. The 
FITC-BSA loaded particles 
were then lyophilized 
overnight. FITC-BSA loaded 
pSi were encapsulated in 
PLGA shell, as described 
above. BSA loading was also 
evaluated by imaging PLGA-
pSi by an A1 confocal laser 
microscopy (Nikon). 
 
3.2.5. Evaluation of FITC-
BSA in vitro release 
2 × 10
8
 FITC-BSA loaded 
PLGA/pSi microspheres 
were divided in three 
aliquots, after dispersing in 
PBS (1.5 ml): each sample 
contained approximately 7 × 
10
7 
particles suspended in 0.5 
ml of PBS. Samples were 
collected, at established time 
intervals, for 1 month. Each 
sample was centrifuged 
(4000 rpm; 5 min), and 10% 
of the supernatant (0.05 ml) 
was collected and replaced 
with fresh PBS. The release of FITC-BSA from the different formulations of PLGA-pSi was quantified by a 
spectrophotometer at 493/518 nm. Samples were collected and analyzed at defined time points, up to 1 month. 
 
3.2.6. Biocompatibility study 
J774 macrophages were utilized for this study (ATCC).  Briefly, murine J774 macrophages were cultured 
according to vendor’s protocols (ATCC), in HG-DMEM supplemented with 10% FBS, 1% penicillin (100 
UI/ml)-streptomycin (100 mg/ml), and 0.25 mg/ml amphotericin B. J774 cells were subcultured by plating them 
into 96-wells plates at a density of 5000 cells/cm
2
 (Millipore). After 24h, cells were treated with PLGA-pSi with 
PLGA 50:50, 75:25 and 85:15, and fabricated with all sizes of pSi (1µm, 3µm and 7 µm). Five different 
concentrations of microspheres were tested, ranging between 0.1 and 10 μg/ml. Viability was evaluated at 72h, in 
triplicate. Cell interaction with PLGA-pSi was initially evaluated by SEM and samples were prepared for imaging 
as previously described (FEI Quanta 400 ESEM FEG, FEI, Hillsboro, OR) [28]. Samples were vacuum dried and 
coated with Pt/Pb and imaged by SEM under a voltage of 8 KV (Hummer 6.2 Sputtering System; Anatech Ltd., 
Figure 3.1 - Images of the different formulations of PLGA-pSi by optical microscopy (bright field). 
PLGA-pSi fabricated with increasing amount of hemispherical pSi (A, B, C) and discoidal pSi (D, E, F); 
scale bar 1 µm. PLGA-pSi made with discoidal pSi of increasing diameter (G, H, I; scale bar 5 µm), 
and bar graphs reporting about the effect of such factors on the overall size of the resulting PLGA-
pSi (L, M). Image of PLGA-pSi prepared with 50:50, 75:25 and 85:15 PLGA copolymer ratios (N, O, P 
respectively; scale bar 20 µm), and their magnification (Q, R, S). Size distribution of the resulting 
sets of PLGA-pSi (T, U, V); scale bar 1 µm. 
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Union City, California). The toxicity of the different formulations and concentrations of PLGA-pSi described 
above was evaluated by MTT assay, according to manufacturer’s protocol (Life Technology).  
 
3.2.7. Subcutaneous injection 
28 BALB/c mice (8 to 12 weeks old) were housed and fed in the animal room at The Houston Methodist Research 
Institute (Houston, Texas) for 48 hours prior to the experiment. The study protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) and performed following GMP standards. All efforts 
were made to minimize the number of animals used for experiments and their suffering. Animals were 
anaesthetized with 2–3 % isoflurane in 100 % oxygen at a flow rate of 1 L/min. A 1 × 1 cm2 area of skin was 
carefully shaved and sterilized. Mice were injected at a dorsal subcutaneous site with 50 μL of a PLGA-pSi 
suspension in PBS. Seven animals per each time point were used. In each animal two injections were performed: 
one as a control (PBS only) and one with the PLGA-pSi suspension. Mice were euthanized at 2h and 3, 7 and 14 
days, by CO2 inhalation and subsequent cervical dislocation 
 
3.2.8. in vivo release study 
One mouse per each time point 
was imaged by Intravital 
microscopy (IV), prior to be 
euthanized, to follow the in vivo 
release of the reporter protein. 
Briefly, the skin was gently 
dissected, flipped and imaged at 
three wavelengths: 610 nm for 
PLGA microsphere (labeled 
with Rhodamine B), 460 nm for 
pSi particles (labeled with 
DAPI) and 516 nm for FITC-
BSA. Region of interest were 
created with a specific tool of 
the software NIS-Element 
(Nikon) to evaluate the diffusion 
of BSA from the microspheres, 
and to verify the confinement of 
the carriers over 2 weeks. 
 
3.2.9. in vivo degradation of PLGA-pSi  
Three subcutaneous pouches of PLGA microspheres were collected and fixed for SEM images in 2.5% 
glutaraldehyde and prepared for SEM evaluation, by dehydration in increasing concentration of ethanol 
(EtOH), as described elsewhere [29]. Samples were sputter coated with 25 nm of Pt/Pb and imaged with a 
voltage of 10 kV, to evaluate the in vivo degradation of the carriers. 
 
3.2.10. Biodistribution  
After imaging of the pouches, organs were collected and homogenized in 20% EtOH in 1M NaOH and incubated 
under mild agitation for 24 hours at room temperature, to further verify confinement of the microspheres. 
Weighted organs (lungs, liver, kidneys, spleen) and PLGA-pSi pouches were then centrifuged at 5000 rpm for 30 
minutes and supernatant was collected, filtered using 0.45 μm nylon centrifugal filter microfuge tubes (VWR) and 
diluted with DI for elemental analysis by ICP-OES (Varian 720 ES, Varian Inc., Walnut Creek, CA) as previously 
described [30].  
 
 
Figure 2.3 - Zeta potential (A), FTIR (B) and TG-DSC analysis. 
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3.2.11. Histological evaluation   
At each time point, one control and one PLGA-pSi pouch were collected and fixed in Optimal Cutting 
Temperature compound (O.C.T.) (Tissue Tek, SAKURA) for histology. Briefly, samples were cut 10 µm thick, 
and sections were washed twice in fresh xylene for 8-10 min and rehydrated sequentially with decreasing ethanol 
concentrations (100%, 95%, 90%, 80%, 70%) and DI water (8-10 min for each step). Histological visualization of 
collagenous connective tissue fibers in tissue sections was achieved using a commercial available kit for 
Trichrome Stain (Abcam; ab150686), according to the manufacturer’s instructions. The air-dried slides were then 
mounted with Cytoseal XYL (Thermo Scientific) mounting medium and then analyzed by Nikon Histological 
Microscope.  
 
3.2.11. Statistical analysis  
Statistics were calculated with Prism GraphPad software. Statistics for experiments was performed using a Two-
Way ANOVA followed by a Tukey’s multiple comparison test. In all cases * was used for p < 0.05, ** for p < 
0.01, and *** for p < 0.001, and **** for p < 0.0001. All experiments were performed at least in triplicates. Data 
is presented as mean ± SD. 
  
 
3.3. Results and Discussion 
 
3.3.1. Evaluation of the morphology and size distribution of PLGA-pSi  
The ability to finely control the shape and size of a carrier for bioactive molecules is crucial to ensure a tight 
control over the physic-chemical properties of the system, its loading efficiency and ultimately its control over the 
release kinetics of the payload. In this study, we investigated the tunability of a composite carrier based on a pSi 
core and an outer polymeric 
shell. Both components are fully 
tunable and can be tailored to 
address any release need. The 
main aim of this study was to 
assess the full tailorability of the 
PLGA-pSi composite 
microspheres and to elucidate the 
role of several foundamental 
variables during the synthesis 
(e.g. size and amount of pSi, 
copolymer ratio of PLGA).  
Hemispherical pSi with a 
diameter of 3µm, (Figure 3.1A) 
and discoidal ones with diameter 
of 1, 3 and 7 µm were fabricated 
(Figure 3.1B). pSi were 
synthesized through an optimized 
lithographic method [20], 
resulting in particles with a 
porosity of 51%. The process 
resulted scalable and reproducible, giving pSi of uniform shape and size, which is key to ensure control over the 
loading and release of the payload.  
However, it has been extensively demonstrated that pSi degradation in biological conditions results very fast and 
thus not compatible with tissue engineering applications [31]. A modified double emulsion method was followed 
to fully encapsulate the pSi in the PLGA microspheres (Figure 3.1C), creating composite microspheres, 
overcoming this limitation and prolongs the release of the payload. PLGA was chosen to synthesize the outer 
shell of the composite microspheres, as it is commercially available in a wide range of copolymer ratios, 
Figure 3.3 - Viability of J774 macrophages when incubated with increasing 
concentrations of the different PLGA-pSi formulations, by MTT analysis (A, B, C). 
SEM images showing the interaction of J774 macrophages with PLGA-pSi (D, E, F); 
scale bar 5 µm. Biodistribution study of Si in the organs respect to the pouch (G). 
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molecular weights and viscosities, which influence the degradation rate of the polymer in vitro and in vivo, by 
modulating its hydrophilic properties, thus also fully tailorable [32, 33].  
Thus, our composite delivery systems has the advantage that can be fully customized to match the user needs, but 
also that by merging pSi and PLGA (a inorganic and organic phase), it is possible to obtain a more stable platform 
when exposed to the fluctuation of the microenvironment of tissues [8, 34-36]. Furthermore, it was demonstrated 
that the two phases degrade in byproducts that act as a buffer, producing a neutral pH, thus avoiding protein 
degradation [24].  
By varying pSi content during the synthesis (2.5, 5 and 10 wt%) we observed an increase in the mean diameter of 
the resulting PLGA-pSi composite microspheres: 5.103 (±0.373) µm for the 2.5wt% pSi in PLGA, 6.435 
(±1.494) µm for the 5wt% pSi in PLGA and 9.013 (±3.230) µm for the 10% pSi in PLGA (Figure 3.2 A, B, C). 
We also attempted the same study with discoidal pSi particles, and we observed a size distribution pattern 
increasing similarly to PLGA-pSi 
prepared with hemispherical pSi 
(Figure 3.2 D, E, F). Similarly, by 
utilizing discoidal pSi of increasing 
diameter (1, 3 and 7 µm) also the 
mean size of the resulting 
microspheres increased accordingly 
(Figure 3.2 G, H, I). The mean 
diameter of all the above mentioned 
formulations of PLGA-pSi are 
reported in the bar graphs in figure 2 
L and M.   
Finally, discoidal pSi were used to 
synthesize PLGA-pSi with 3 
different copolymer ratios: 50:50, 
75:25 and 85:15. At higher 
copolymer ratios the overall size of 
PLGA-pSi increased (Figure 3.2 N, 
O, P) and resulted in a higher 
content of pSi particles (Figure 3.2 
Q, R, S). PLGA-pSi fabricated with 
50:50 and 85:15 copolymers 
displayed a superior size distribution 
respect to that made with 75:25 PLGA, which appeared including 3 distinct subpopulations of microspheres, and 
thus resulting to be less reproducible.  
 
3.3.2. Physicochemical characterization of PLGA-pSi  
In order to diminish the hydrophobicity of the particles and enhance their loading efficiency, particles surface was 
firstly oxidized by etching [37]. This steps allowed for the introduction of hydroxyl groups on the surface of the 
silicon particles, and to allow for the addition of amine groups by surface modification with APTES. Zeta 
potential analysis showed a mean surface charge of 6.737 mV after APTES modification, versus the initial value 
of -30.39 mV (Figure 3.3 A). The capacity of FITC-BSA (and bioactive proteins) to be loaded onto the pSi 
particles is affected by the surface characteristics. BSA, in fact, had a negative charge and the electrostatic 
interaction between amine groups of APTES and acidic moieties of BSA intensified the ability of FITC-BSA to 
be loaded into the pores of pSi particles.  
Figure 3.4 - Cumulative release of FITC-BSA from the different formulations of 
PLGA-pSi (A, B, C). Amount of BSA (ng) released daily from PLGA-pSi with 
formulation PLGA 85:15/pSi 1 µm. 
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PLGA-pSi were also characterized by FTIR 
spectroscopy. The analysis showed a 
broadening of peaks corresponding to the 
stretching of Amide I (1750–1735 cm−1), 
suggesting the ionic interaction of the 
carbonyl groups on the surface of the PLGA 
with the amine groups of APTES-modified 
pSi (Figure 3.3 C).  
Finally, TGA analysis was performed for 
PLGA-pSi 85:15 with different amount of pSi 
(2.5, 5 and 10wt %). Results are shown in 
Figure 3 D. pSi content for the three 
formulations resulted in the 2.674 wt%, 2.660 
wt% and 7.427 wt%, respectively. From DSC 
analysis it was observed an increase in the Tm 
of PLGA-pSi respect to empty PLGA 
microspheres (used as a control) of 
approximately 15ºC, proving the existence of 
a chemical interaction between pSi and the 
polymer. Also among the three formulations 
of PLGA-pSi, the heat flow value of those 
endothermic reactions resulted progressively 
decreased at higher contents of pSi.  
 
3.3.3. Evaluation of FITC-BSA release 
kinetics in vitro 
The temporal control over the release of the 
payload is fundamental to guarantee the proper therapeutic effect, for the necessary window of time. In fact, the 
tight regulation of the dose of bioactive molecule released daily allows avoiding side effects due to overdoses or 
the progression of the pathological state due to an insufficient amount of drug.  
The release of FITC-BSA was assessed over a month. What resulted evident from the release study was that the 
increase of the copolymer ratio of the PLGA coating, enabled for the progressive reduction of the initial burst 
release (Figure 3.4), and a slower release rate. This was probably due also to the fact that the FITC-BSA was 
found secured in correspondence of the pSi core, and thus protected from the environment, avoiding burst release 
(Supplementary figure 1). 
Also, we found that the bigger the size of the pSi microspheres utilized in the preparation of the PLGA-pSi, the 
slower was the release of the reporter protein.  
However, using progressively bigger sizes of pSi, we observed higher variability in the amount of protein released 
daily. The daily release of FITC-BSA for the formulation PLGA-pSi 85:15/pSi 1 µm resulted the most consistent 
(approximately 12 ng/day), and it is reported in figure 4 D.  
The main goal of this study was the ability to fully tailor the PLGA-pSi to accomplish a temporal and spatial 
control over the release of proteins in vivo. Thus, as a proof of concept, we chose this PLGA-pSi formulation 
(PLGA 85:15/pSi 1 µm) as the most reproducible in terms of size and control over the release (lower standard 
deviations), as well as characterized by no initial burst release.  
 
3.3.4. Biocompatibility  
Macrophages have been demonstrated to be one of the first type of immune cells to intervene at the site of injury 
[38]. Thus, we simulated the in vitro response to the PLGA-pSi by incubating murine macrophages with 
increasing concentrations of PLGA-pSi of different formulations.  
Macrophages’ viability resulted not significantly compromised by increasing concentrations of PLGA-pSi (both 
made with 1 and 3 µm pSi) (Figure 3.5 A, B). We observed that with PLGA-pSi made with 7 µm pSi, their 
Figure 3.5 - Fluorescence images acquired by intravital microscopy to 
evaluate the in vivo release over 2 weeks. PLGA shell is represented in red , 
pSi in blue  and BSA in green. Scale bar 1 mm. 
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viability slightly decreased by increasing the amount of PLGA-pSi in the media, but remained above 80% (Figure 
3.5 C). Macrophages’ interaction with PLGA-pSi of different sizes is depicted in Figures 3.5 D, E and F, which 
show cells engulfing PLGA-pSi or surrounding them when bigger than their size (approximately 8-10 µm in 
diameter).  
 
3.3.5. in vivo spatially controlled release  
Ultimately, we wanted to assess if the ability to control the spatial and temporal control over the release of FITC-
BSA accomplished in vitro, was preserved in vivo. The release of the reporter protein was followed over 14 days, 
in the mouse subcutaneous model. In figure 3.6 A are presented the images acquired by IV. The panel shows that 
both PLGA (red) and pSi (blue) signals overlap for all the window of time considered. This was further 
demonstrated by the fluorescence intensity plot, in which the fluorescence signals of the three components of the 
carrier not only overlap, but it shows that the outer layer of the system is the PLGA (red), the middle one is pSi 
(blue) and the inner component is the FITC-BSA (green). Concerning FITC-BSA, it is possible to identify a slight 
diffusion of the protein outside the area where PLGA-pSi were localized. However, the BSA diffused in the 
immediate surroundings of the microspheres (distributed over an area of 1.148 cm
2
) over a maximum area of 
4.778 cm
2
, thus demonstrating the ability of PLGA-pSi to retain FITC-BSA at the earliest time point, avoiding the 
initial burst release, as characterized in vitro.  
After IV, the pouch was also imaged by SEM, to better evaluate the morphology and degradation of PLGA-pSi. 
Figure 7 depicts the microspheres after injection, at day 3, 7 and 14. At all time points it is possible to identify 
PLGA-pSi microspheres, as indicated by the white arrows.  
If internalized by phagocytes (see paragraph 3.3.4), PLGA-pSi would be cleared out and transported to the 
spleen, or the kidney, for example. Thus, we finally evaluated the spatial control over the payload by evaluating 
the confinement of pSi in the pouch.  
ICP analysis of the content of Si in mice’s organs showed that at day 1 more than 85% of Si was found in the site 
of injection, while progressively decreasing over a month (54% at 14 days and 18% at 30 days), mirroring the 
sustained release of the protein in vitro.  
After IV, the pouch was also imaged by SEM, to better evaluate the morphology and degradation of PLGA-pSi. 
Figure 3.7 depicts the microspheres after injection, at day 3, 7 and 14. At all time points it is possible to identify 
PLGA-pSi microspheres, as indicated by the white arrows.   
 
 
 
Figure 3.6 -- SEM micrographs of the microspheres found in the pouches at day 0, 3, 7 and 14 after injection in the 
mouse subcutaneous model. Scale bar panels A-D 100 µm, E-F 30 µm. 
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3.3.6. Histology 
Panel in figure 3.8 shows the pouch up to 14 days after injection, compared to the control. The images of the 
controls immediately after injection (of PBS), presented fibers and a minor accumulation of cells, which resolved 
over the two weeks evaluated. In the pouches injected with PLGA-pSi, at day 0 it was observed the accumulation 
of fibers (blue) and of a few cells, similarly to what was found in the control samples. Within two weeks the outer 
polymeric shell (labelled with Rhodamine B), started to slowly degrade, and release part of the dye, as it can be 
noticed by the more intense red color of the slides. All together these data confirm the controlled process of 
degradation of PLGA-pSi in vivo, which reflected in a slow and sustained release of the reporter protein, within 
the pouch.  
 
3.4. Conclusions 
In summary, we have demonstrated the full tunability of PLGA-pSi composite microspheres. This kind of 
composite carrier combines the advantages of mesoporous structures to be loaded with high amount of proteins, 
due to their high surface area, and the plasticity and tailorability of polymers. In this study the formulation which 
accomplished the most controlled and sustained release was tested in vivo, to demonstrate the temporal and spatial 
control over the release of the payload. However, depending on the application, it is possible to envision the use 
of other formulations, and also the combined use of multiple formulations of PLGA-pSi. They also result greatly 
advantageous by being injectable, which would allow for an easy administration of a molecule of interest, once a 
month, while showing low toxicity. These results assessed in vivo that PLGA-pSi represent a robust, reproducible 
and scalable platform to be translated in the clinic, for applications of tissue regeneration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 - Hystological evaluation of the pouches at day 0, 3, 7 and 14 after injection of PLGA-pSi 
in the mouse subcutaneous model. Scale bar 20 µm. 
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CHAPTER 4 
 
 
MULTISCALE PATTERNING OF 
BIOMIMEITC SCAFFOLDS 
 
 
 
 
4.1. Introduction 
The fate of a cell is determined by a complex set of biomolecules, which create the tissue-specific biochemical 
milieu, and by the nano- and micro-scale physical features that ultimately define tissues macroscopically [1]. The 
elucidation of the stimuli necessary to achieve proper tissue regeneration has focused scaffolds’ design toward the 
mimicry of the chemical and structural determinants of the tissue of choice [2, 3]. A wide range of signaling 
molecules has been utilized to enhance the recruitment, proliferation and differentiation of autologous cells in the 
scaffolds. As an example, Bone 
Morphogenetic Protein-2 
(BMP-2)[4]  and Transforming 
Growth Factor Beta (TGF-β) 
[5], are extensively used for 
bone and cartilage regeneration. 
A plethora of biomaterials 
based on polysaccharides (e.g. 
hyaluronic acid and alginate), 
proteins (e.g. fibrin, gelatin, and 
collagens) or synthetic polymers 
(e.g. poly(lactic acid) (PLA), 
poly(lactic acid)-co-(glycolic 
acid) (PLGA)) have been tested 
for tissue engineering 
applications [5-7]. Collagen has 
attracted material scientists 
because it is one of the main 
components of human tissues. 
Its fibers spontaneously 
organize in supra-molecular 
networks, whose nano-topography is critical for conserving both biochemical (protein adsorption and growth 
factor retention) [8] and biological (cell adhesion, migration, and differentiation) mechanisms [1]. The initial 
strategy was to add the growth factors by directly soaking the scaffold in a solution containing the factors of 
choice [9]. Unfortunately, a recent controversy spurred from the adverse effects of excessive and uncontrolled 
release of recombinant human – BMP-2 in patients treated with collagen implants for spine fusion, brought the 
attention on the need to control the spatial and temporal distribution of the growth factor in the scaffold [10, 11]. 
Figure 4.1 - Characterization of PLGA-pSi microspheres. (A) SEM image of pSi 
illustrating their typical quasi-hemispherical shape; (B) Maximum, mean, and 
minimum pSi size; (C) SEM image and (D) size distribution of PLGA-pSi microspheres 
and number of pSi per PLGA microsphere. (E) Optical microscope image of PLGA-pSi 
composite microspheres (PLGA: transparent sphere; pSi: brown hemispheres); (F) 
sliced view of a PLGA-pSi microsphere showing full integration of pSi. 
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To recapitulate how these growth factors are naturally presented, it is necessary to engineer scaffolds able to 
mimic the sequential release of multiple molecules from various intra-scaffold compartments [12, 13]. The 
control of the material’s structure at the nano-, micro- and macro-scale is of paramount importance to ensures the 
optimal three dimensional (3D) release and distribution of bioactive factors [14, 15]. Nanostructured porous 
silicon [16] revealed a valuable material in tissue engineering for its osteoconductivity [17, 18], and to develop 
porous particles able to accommodate high amount of proteins [19]. Thus, pSi has been efficiently incorporated in 
a wide range of synthetic polymers for composite scaffolds’ fabrication [20, 21], or for the development of 
composite delivery systems able to load, store and release multiple proteins from days to weeks and months [22, 
23]. These composite delivery platforms have the advantage to be easily tunable to match their release rates to 
those of native tissue, and to be more stable than the scaffold in which the delivery systems were added through 
surface adsorption [24-26]. The lack of a tight confinement and protection of the delivery systems implies that 
once the scaffolds are implanted, they are exposed to the fluctuation of the microenvironment (e.g. pH, enzymatic 
activity, abnormal accumulation of fluid, etc) and to phagocytic cells of the immune systems which alter the 
composition of the scaffold and the stability of its individual components [27]. However the dispersion of 
particles in a microfibrous polymer such as natural type I collagen is challenging as well as the homogenous and 
effective retain of the particles in the final 3D scaffold. Type I collagen has the advantage to closely resemble 
ECM, but its hierarchically organized fibrous structure does not allow the use of the common methods of 
fabrication (e.g. electrospinning, sonication), without affecting its structure, which is key for its biological 
functions [28]. Here we propose a systematic approach for the synthesis of multiscale fibrous type I collagen 
scaffolds patterned with PLGA–pSi composite microspheres for the temporal and spatial release of proteins, 
addressing all the current limitations. This proof of concept study shows that the integration of the delivery 
systems within the two layers of a collagen scaffold, allows the triple-controlled release of two reporter proteins, 
the spatial confinement of the microspheres and the preservation of the nano- micro- and macro-scale features of 
the scaffold. 
 
4.2. Materials and Methods 
 
4.2.1. Silicon Particles Fabrication and Surface Modification 
Hemispherical porous silicon particles of 3.2 µm in diameter and 600 nm thick were fabricated by 
photolithography and electrochemical porosification of patterned silicon wafers, allowing for precise control over 
particle size and shape, as previously reported [23, 29]. Silicon particles were oxidized as extensively described 
elsewhere [23, 30]. The surface of the pSi particles was modified with APTES (Sigma–Aldrich) as previously 
described [23, 29]. 
 
4.2.2. PLGA-pSi Optimization and Characterization 
2 × 108 APTES modified pSi were dispersed, by sonication, in a solution of PLGA (50:50) (LACTEL) dissolved 
in dichloromethane (DCM) (375 µL, 50 mg/ml) (Sigma-Aldrich). The organic phase containing the pSi was 
mixed with poly (vinyl alcohol) (PVA) (Fisher Scientific) (1,5 mL, 25 mg/ml) by homogenization. The emulsion 
was dropped into an aqueous solution (50 mL) containing PVA (5 mg/ml). The resulting suspension was stirred 
for 6 h to allow the evaporation of the dichloromethane, then washed three times with DI water. Empty PLGA 
microspheres were eliminated by differential centrifugation, as we previously implemented [23]. PLGA-pSi’s 
morphology of the microspheres was characterized by SEM (FEI Nova NanoSEM 230). They were sputtered 
coated by a Plasma Sciences CrC-150 Sputtering System (Cressington 208HR), and examined under a voltage of 
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7 KV. Also, they were imaged through optical microscopy (Nikon Eclipse TS 100), and PLGA-pSi size 
distribution was measured though an automated measurement tool of the software NIS-Element (Nikon).  
 
4.2.3. Preparation of the collagen slurry 
1 g of type I collagen (Sigma-Aldrich) were dissolved in an acetate buffer (pH 3.5) to reach the desired 
concentration (20 mg/ml) [31]. The collagen suspension was precipitated by the addition of sodium hydroxide 
(0.1 M) solution at pH 5.5. The collagen was washed three 
times with DI water. The collagen was cross-linked through 
dispersion for 48 h in a 1,4-butanediol diglycidyl ether 
(BDDGE) (Sigma-Aldrich) aqueous solution (2.5 mM), 
setting up the 1, 4-butanediol diglycidyl ether 
(BDDGE)/collagen ratio (1 wt%) [31]. The collagen was 
washed 3 times in DI water.  
 
4.2.4. Fabrication of CTRL, ADS and INT scaffolds 
The cross-linked collagen (20 mg dry weight) was suspended 
in DI water (5 mL), and three groups of collagen scaffolds 
were fabricated: (i) CTRL; (ii) ADS; (iii) INT. To fabricate 
the ADS, PLGA-pSi were suspended in water (2 mg/mL) and 
the scaffolds were swollen in the dispersion. The same 
amount of particles was instead integrated during fabrication 
of INT, at their slurry state. The materials were freeze-dried 
with a controlled freezing ramp from 25 °C to -25 °C and a 
heating ramp from -25 °C to 25 °C in 50 min under vacuum 
conditions (P = 0.20 mbar), and collagen scaffolds (20 mm3) 
were produced. Blank collagen scaffolds were used as CTRL. 
The evaluation of scaffolds morphology was performed 
through SEM. A set of fluorescently labeled PLGA-pSi were 
prepared for confocal laser microscopy imaging (A1 Nikon 
Confocal Microscope). PLGA was labeled with Rhodamine B 
(Sigma-Aldrich), while pSi was conjugated with Dylight488 
(Invitrogen) [32]. The blending of PLGA-pSi and collagen 
was also validated through FTIR (Nicolet 6700 FT-
IR Spectrometer).  
 
4.2.5. Pore Size, Porosity and Swelling 
1 mm thick sections of the scaffolds were imaged with 
fluorescence microscopy (Nikon Eclipse Ti equipped with a 
Hamamatsu Orca Flash 2.8 digital camera), and the pore are 
determined via an automated measurement tool of the NIS-Element software (Nikon). The volumes of the 
scaffolds (Vs) were measured from the scaffold geometry (cylinders of 5 mm in diameter and x 1 mm height). 
The volume of the pores was calculated by an ethanol infiltration method [33]. The volume of the pores was 
defined as in Equation: Vp = (We - W0)/ρe, where W is scaffold’s weight before (W0) and after incubation in 
ethanol (We), and ρe (0.789 mg mL–1) represents the ethanol density at room temperature. The porosity of the 
Figure 4.2 - Scaffold integrated with PLGA-pSi 
microspheres. (A, B, C) Scanning electron microscopy 
images at different magnifications of control 
collagen scaffold (CTRL); (D, E, F) scaffold with PLGA-
pSi adsorbed (ADS) on the surface and (G, H, I) with 
PLGA-pSi integrated (INT). (J) Type I collagen created 
a coating on the microspheres, indicated by the 
arrows, (K, L) while preserving collagen 
ultrastructure. 
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scaffolds was calculated according to Equation P = Vp/Vs · 100%. To determine the PBS uptake property, the 
completely dried scaffolds were weighted and afterwards incubated in PBS at 37 °C. The hydrated scaffolds were 
taken out at the desired time intervals, wiped superficially with a filter paper to remove the surface water, and 
weighed (Ww). The value is expressed as means ± SD (n = 5). The uptake ratio was defined as swelling %, as in 
Equation Sw% = (Ww - Wd)/Wd · 100. 
 
4.2.6. PLGA-pSi Integration Assessment 
PLGA-pSi confinement stability over time was investigated incubating the CTRL, ADS and INT scaffolds (5 per 
group) in PSB at 37°C in mild mixing (100 
rpm). Particle loss was quantified counting 
the fluorescently labeled microspheres 
(Rhodamine B) through the automated 
counting tool of the NIS-Element Software 
(Nikon) of the fluorescence microscope, 
collecting the PBS and substituting it with 
fresh one at defined time points, up to 2 
weeks. Also, other 5 scaffolds, with the same 
formulation were used to assess PLGA-pSi 
distribution in ADS and INT.  
 
4.2.7. Loading of 488-BSA and 680-BSA 
into APTES modified pSi particles 
488-BSA and 680-BSA (FITC-BSA, Sigma–
Aldrich; Dylight680-BSA, Invitrogen) 
solutions (10 mg/mL) were prepared by 
dissolving the BSA powder in DI water. 2 x 
108 APTES modified particles were 
immersed into the 488-BSA (Sigma-Aldrich) 
and 680-BSA (Invitrogen) solution (500 μL) 
respectively. The suspensions were mixed at 
37 ºC for 2 h, to allow proteins loading in the 
pores of the pSi. The particles were 
recovered by centrifugation at 4000 rpm and 
washed three times with PBS to remove the 
488-BSA or 680-BSA adsorbed on the surface. The particles were then lyophilized overnight. The amount of 
protein loaded was measured by the difference between the protein concentrations of the stock solution and of the 
supernatant using SpectraMax M2 spectrophotometer (Molecular Devices) at 493/520 nm and 680/715 nm to 
quantify 488-BSA and 680-BSA, respectively.  
 
4.2.8. Loaded pSi encapsulation in PLGA-pSi 
BSA-loaded pSi particles were coated with PLGA by a modified S/O/W emulsion method, as described above. 
Briefly, 2 × 108 488-BSA and 680-BSA loaded pSi were dispersed, by sonication, in PLGA (50:50) (LACTEL) 
dissolved in DCM (375 µL) (Sigma-Aldrich) (50 mg/ml and 200 mg/mL). Thus, two sets of PLGA-pSi with 
different PLGA coating were obtained as follow: 5 wt% (LD) and 20 wt% PLGA in DCM (HD). A quantitative 
Figure 4.3 - Qualitative analysis of PLGA-pSi blending with collagen 
matrix. (A) 3D reconstruction of confocal microscopy images 
illustrating PLGA-pSi integrated in the collagen scaffold and 
completely wrapped by collagen (collagen: blue; PLGA: red; pSi: 
green); (B) sagittal view showing pSi encapsulated within PLGA and 
coated by the collagen matrix. (C) FTIR patterns of the multiscale 
components of PLGA-pSi and (D) of the functionalized scaffold. 
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characterization to assess the PLGA and pSi content in the two formulations (LD and HD) was performed via 
thermogravimetric analysis (TA Instruments Model Q600), with a heating ramp of 5°C/minute, from 25°C to 
500°C. 
 
4.2.9. Bi-layered BSA-loaded scaffold fabrication 
PLGA-pSi loaded with 488- or 680- BSA were dispersed in 1 mL of DI water and added to separate crosslinked 
collagen slurries (as described above), mixed and finally centrifuged at 4000 rpm in a Legend X1R Centrifuge 
(Thermo Scientific) for 5 minutes. Through layer-by-layer assembly the two collagen slurries were piled on to 
each other, in a metallic mold. Finally, a monolithic scaffold was generated through freeze-drying process as 
described above. Scaffold’s morphology 
was characterized by SEM, fluorescence 
and confocal laser microscopy.  
 
4.2.10. Evaluation of 488- and 680- 
BSA in vitro Release 
As a control, LD and HD were dispersed 
in phosphate buffer saline (PBS) (20 
mL) at 37 °C. Also by-layered scaffolds 
ADS and INT were immersed in PBS in 
glass bottles as well as CTRL, at 37°C, 
and mixed at 100 rpm. At predetermined 
time intervals, the suspension was 
centrifuged (4500 rpm; 5 min), and 10% 
of the total volume of supernatant (2 
mL) was collected, and replaced with 
fresh PBS, up to 50 days. The release 
was quantified by SpectraMax M2 
spectrophotometer (Molecular Devices) 
at a wavelength of 493/520 nm and 
680/715 nm to quantify 488-BSA and 
680-BSA respectively. Three replicates 
for each experimental group were utilized.  
 
4.2.11. Statistical analysis 
The number of samples used in each experiment is noted in the text of the experimental section. Dependent 
variables are expressed as means ± SD. The differences in the means were tested using ANOVA and Student T-
test to check for statistical signiﬁcance (P < 0.05). 
 
4.3. Results and Discussion  
 
4.3.1. Nano- and Micro-Patterning of the Scaffold 
Nanostructured porous silicon particles (pSi) have been chosen as the core of the delivery systems for their 
biocompatibility [34], controllable biodegradation [22], high porosity (51%) and thus surface area [29], that allow 
for the storage and preservation of high amounts of different payloads (Figure 4.1A, B) [16, 32]. The ability to 
Figure 4.4 - Characterization of blended scaffolds. (A) Fluorescent image 
of the entire collagen scaffold at low and (B) high magnification used for 
pore area calculation. (C) Porosity and pore area of scaffolds adsorbed or 
integrated with PLGA-pSi compared to a control scaffold. (D) Swelling 
characteristics comparing control, adsorbed (ADS), and integrated (INT) 
collagen scaffolds over time. 
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tailor the physicochemical properties of porous silicon at the nano- and micro-scale confers versatility to this 
material [29]. Also, their preparation method allows for the fabrication of highly reproducible, monodisperse 
particles, favoring their loading and encapsulation [23, 30, 32].  pSi shells were fabricated with an average 
diameter of 3.2 μm, 600 nm shell thickness.  To improve loading efficiency, pSi surface was modified with  (3-
Aminopropyl)triethoxysilane (APTES) that increases its hydrophilicity by introducing amine groups on the 
surface of the particles [30].   
 
4.3.2. pSi Encapsulation in PLGA Microspheres 
Although silicon revealed a valuable materials to develop delivery systems able to load, store and release multiple 
proteins, their degradation in physiologic conditions resulted very fast (in the order of hours) [22], and thus not 
compatible with tissue healing, which take place from several weeks, up to months. The creation of composites, 
based on pSi and polymers, contributes to enhance material stability and thus prolong release kinetics.  
PLGA can be produced in different molecular weights and copolymer ratios, yielding materials with tunable 
degradation rates [35, 36]. To obtain the stable and efficient blending with pSi in the organic solvent and the 
following integration with collagen in an aqueous solution, we used the 50:50 PLGA co-polymer that resulted in 
the optimal surface charge and polarity. pSi were encapsulated in the PLGA shell through a modified double 
emulsion method [23]. The use of monodisperse pSi was key to optimize PLGA-pSi size distribution, as 
confirmed by scanning electron microscopy (SEM) (Figure 4.1C), where PLGA-pSi displayed an average size of 
11 ± 3 µm in diameter (Figure 4.1D, blue data set), with sizes ranging between 3 μm to 25 μm, with a reduction of 
the size range of the 50% compared to previous reports [37]. Optical microscopy demonstrated that median 
number of 3 (±0.2307) pSi (Figure 4.1D, yellow data set) were encapsulated in the PLGA microsphere (Figure 
4.1E, F). The overall improvement of PLGA-pSi fabrication and pSi dispersion through the microspheres was 
crucial to ensure a more homogenous release of payload. 
 
4.3.3. Collagen Functionalization with PLGA-pSi 
Collagen type I was chosen because it is the most abundant structural element in connective tissues [38, 39], 
where its hierarchically organized structure plays a prominent role in maintaining the biologic and structural 
integrity of the ECM [40]. Exploiting collagen’s ability to dock and blend with PLGA, we optimized a procedure 
to stably integrate PLGA-pSi within the scaffold’s matrix. To demonstrate the spatial confinement of the 
miscrospheres in the scaffold we compared three groups: (i) blank scaffolds (CTRL); (ii) scaffolds with adsorbed 
PLGA-pSi microspheres (ADS), included as current standard; (iii) scaffolds with PLGA-pSi integrated in the 
collagen matrix (INT). Figure 4.2 illustrates the morphology and microstructure of the CTRL (Figure 4.2A, B, C), 
ADS (Figure 4.2D, E, F) and INT (Figure 4.2G, H, I) scaffolds. The PLGA-pSi fully integrated within the 
collagen matrix of INT scaffolds, while in the ADS scaffolds the microspheres were simply adsorbed on the pore 
walls. In fact, the collagen matrix formed a consistent coating surrounding the PLGA-pSi, as illustrated in Figure 
4.2J, where a high voltage electron beam during SEM imaging was used to damage the collagen coating and 
expose the PLGA-pSi. The overall morphology of the scaffolds and their pore shape and size were preserved in 
both ADS and INT scaffolds. Similarly, PLGA-pSi did not affect the structure of the collagen fibrils which 
maintained the characteristic D-band of approximately 67 nm (Figure 4.2K, L) [41, 42]. Thus, herein we 
developed a method of scaffold functionalization with PLGA-pSi which preserves such asset, and which is also 
exploited as a further level of control over the temporal and spatial control over the reporter proteins.  
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Table 1.Comparison of the characteristics of ADS and INT respect to their controls. 
 
 CTRL ADS INT 
Pore Area 
[µm2] 
 
20.3·103 
 
14.3·103 
 
18.4·103 
Porosity 
[%] 
91 83 88 
PLGA-pSi Diameter 
[µm] 
 
11 ± 3 
 
10 ± 4 
 
10 ± 3 
Mean Distance of PLGA-pSi 
[µm] 
/ 70±21    46 ±7 
 
4.3.4. Characterization of PLGA-pSi Integration in Collagen Scaffolds 
To confirm the complete embedding of the PLGA-pSi within the collagen matrix, confocal laser microscopy was 
used to acquire Z-stacks, and reconstruct the 3D volume around the integrated microsphere (Figure 4.3A). As 
exposed in the orthogonal views in Figure 4.3B, the fibers of the collagen (blue) completely enclosed the PLGA-
pSi (red and green, respectively). Pore wall’s thickness was measured from the Z-stack acquisitions, and appeared 
to be in the range of 10-15 µm in the control scaffold. By embedding PLGA-pSi of ~11 µm, in the collagen 
matrix we provided a ≤ 2 µm thick collagen coating of PLGA-pSi. Reaching a more homogenous distribution of 
PLGA-pSi along the pore walls, as well as the consistent thickness of the collagen coating on all microspheres, 
was crucial for a homogenous release from the bulk scaffold. Microspheres’ blending with the collagen matrix 
was analyzed through Fourier transformed 
infrared spectroscopy (FTIR). CTRL, INT 
scaffold and ADS scaffold have been all freeze 
dried following the same procedure, previous 
FTIR analysis. FTIR spectra of PLGA-pSi 
microspheres resembled a hybrid spectra, 
resulting by the addition of the peaks of pSi and 
PLGA, confirming the formation of a pSi-PLGA 
composite (Figure 4.3C). In the INT scaffolds 
(Figure 4.3D), a pattern with broader FTIR peaks, 
especially in the regions that correspond to amine 
groups (3500-3300 cm-1, stretching) [43], and 
carbonyl groups (1750-1735 cm-1, stretching) car 
be observed [44], suggesting the interaction of the 
carbonyl groups on the surface of the PLGA-pSi 
microspheres with the amine groups of the 
collagen. A moderate contribution in the 
broadening of the Amide I peaks of INT scaffold 
by physisorbed water was excluded for the 
absence of any broadening in the correspondent peak in CTRL. On the contrary, the Amide I peak intensity and 
area in the range 3000-3600 cm-1 (OH- stretching) are comparable in both samples, and do not appear to be 
affected by the presence of physisorbed water. On the contrary, the FTIR spectra of ADS scaffolds displayed 
either the spectrum of pure type I collagen or of PLGA-pSi, depending on the spot analyzed (10 random  spots 
were evaluated). Analysis of the mean pore size and surface area confirmed the anisotropic structure of all 
Scheme 1 - Schematic showing: (A) the setting of LD PLGA-pSi 
(PLGA: blue; pSi: green) and HD PLGA-pSi (pSi: red), in the 
collagen fibers (yellow), (B) in the bi-layered collagen scaffold. 
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scaffolds (Figure 4.4A and B) [31, 45]. CTRL presented a porosity of 91%, with a mean pore area of 20·103 µm2, 
and with a diameter in the range of 250-350 µm. The changes in the average porosity and pore area of ADS and 
INT, respect to CTRL, are shown in Figure 4C. While the integration of PLGA-pSi did not result in a significant 
decrease of the porosity in the INT scaffolds, the pore size and porosity of ADS scaffolds were significantly 
different from CTRL. This discrepancy was attributed to the obstruction of the pores by the adsorbed 
microspheres. The swelling of both ADS and INT scaffolds was slightly lower than the control scaffold, though 
not significantly altered, and demonstrated that the integration of PLGA-pSi in the collagen matrix did not affect 
its swelling, a key feature for both the mechanical and biological properties of the scaffold (Figure 4.4D). Pore 
size and porosity of the scaffold were tuned during the freeze drying process through the adjustment of the 
freezing temperature, heating ramp, and the content of water in the collagen slurry [46].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 - PLGA-pSi functionalized bi-layered scaffold. (A) SEM, (B) fluorescent and (C) bright field 
images, merged with fluorescence, of the interface between the two layers of the collagen scaffold 
functionalized with LD loaded with 488-BSA (green layer) or HD loaded with 680-BSA (red layer). (D, 
E) Maximum intensity projections and 3D reconstruction of CTRL, (F, G) LD INT layer and (H,I) HD INT 
layer, respectively. 
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None of these features were affected by the incorporation of the PLGA-pSi microspheres. Confocal imaging of 
the scaffolds allowed the identification and characterization (e.g., diameter, distribution, and relative distance) of 
individual microspheres within scaffolds (NIS-Elements software, Nikon). The density of microspheres in the 
ADS and INT scaffolds was 2·10
3
 (± 24) per mm
3
. The type of integration did not change the size of PLGA-pSi 
confirming the stability of the microspheres throughout the integration process. The mean distance between 
PLGA-pSi was calculated automatically in ten random positions on the Z plane. For INT scaffolds, the mean 
distance between neighboring PLGA-pSi was 46 µm. The moderate standard deviation supports the homogenous 
distribution of microspheres within the INT scaffolds. On the other hand ADS scaffolds, possibly due to the 
uncontrolled distribution and agglomeration of PLGA-pSi, exhibited mean distances of 70 μm, correlating with a 
much higher standard deviation. All these data are summarized in Table 1. Through the tuning of the design 
parameters (PLGA-pSi size, density, number of PLGA-pSi per layer, mean distance between microspheres, etc.), 
it is possible to reverse engineer scaffolds with pre-defined parameters, to allow for the customization of scaffolds 
with defined geometries, release patterns and kinetics. 
The stability of the integration of PLGA-pSi in the scaffold was tested comparing the retention of microspheres 
from ADS and INT scaffolds. After two soaking steps, ADS scaffolds lost three times more PLGA-pSi than INT 
(15% and 5% respectively). At two weeks 94% of PLGA-pSi was lost from the ADS scaffolds, compared to only 
17 % lost from INT, exhibiting an almost 6 fold increase in retention. The role of the collagen in retaining 
scaffold’s nano- and micro- components and features (e.g. functional groups, hierarchical architecture, pore size, 
swelling), ultimately preserving the entire macro-structure, enabled the stable and homogeneous confinement of 
PLGA-pSi. All these results confirmed that PLGA-pSi became part of the scaffold, when integrated to the 
collagen at the slurry state, during the last steps of fibers self-assembling. All these data together demonstrated 
that this approach of functionalization represents a more efficient alternative to particle adsorption in collagen 
sponges, which lack of any control over particles’ distribution and retention. 
 
4.3.5. Macro-patterning of the Scaffold with PLGA-pSi  
 
4.3.5.1. Spatial Patterning of the Reporter Protein 
A bi-layered scaffold for the staged release of 488-BSA and 680-BSA from each individual layer was fabricated 
according to Scheme 1. 488-BSA was encapsulated in a PLGA-pSi with a low-density polymer (LD) coating to 
achieve a faster release rate; while 680-BSA was incorporated in high-density polymers (HD) for a slower release 
rate. Composites were characterized also by Thermo-Gravimetric Analysis to confirm the different content of 
polymer and silicon. Quantification of BSA loading revealed that 12 ± 3 µg of 488- or 680-BSA was 
accomodated into 106 pSi exhibiting no appreciable loss of BSA during encapsulation with PLGA. The high 
loading capacity of the pSi core facilitates the prolonged release of proteins and is amenable to the concurrent 
loading of multiple bioactive factors. This is particularly relevant as most clinical applications require hundreds of 
nanograms of bioactive factors per day to achieve an effective dose [47, 48]. The structure of the bi-layered 
scaffold and of each layer is depicted in Figure 4.5. PLGA-pSi microspheres were completely enclosed within the 
collagen layer forming the pore walls. The interface between the two layers exhibited no delamination and near-
perfect integration (see dotted line in Figure 4.5A). The optimized freeze-drying process led to a monolithic 
scaffold showing structural continuity between different layers (Figure 4.5B and C), and devoid of signs of 
delamination under physiological conditions. When the two layers are stacked at their slurry state the exchange of 
fibers between the unstructured collagen molecules allow the interweaving of the two layers. The controlled 
freezing and heating ramp, triggered the directional growth of water crystals from the bottom to the top of the 
slurry, resulting in further integration and stability of the two layers. This fabrication technique allowed for the 
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creation of several intra-scaffold compartments in which the confinement of the PLGA-pSi occurred in all 
dimensions. The ability to accomplish the 3D patterning of the scaffold is particularly relevant for applications in 
interface tissue engineering, where there is the need to simultaneously mimic the architecture and biochemical 
environments found at the interface of different but contiguous tissues [49]. 
 
 
4.3.5.2. Temporal Patterning of the Reporter Proteins: In Vitro Release 
To investigate the contribution of the collagen scaffold to the release kinetics of BSA from LD and HD PLGA-
pSi, we investigated four experimental groups: (1) LD and HD; (2) 488- and 680-BSA soaked in a bilayered 
collagen scaffold (SKD); (3) LD and HD adsorbed in a bi-layered (LD/HD ADS); (4) LD and HD integrated in a 
bi-layered scaffold  (LD/HD INT).  The release kinetics of each experimental group are reported in Figure 4.6A. 
For clarity, a single release profile was reported for SKD, as the release kinetics for 488- and 680-BSA were 
Figure 4.6 - Release kinetics from bi-layered functionalized scaffolds. (A) Overall results of all the groups 
investigated. (B) Release of BSA from SKD, LD PLGA-pSi and LD PLGA-pSi ADS. (C) Comparison of BSA release 
from LD PLGA-pSi and INT. (D) Comparison of BSA release from HD PLGA-pSi and INT. The statistical 
significance between the amounts of BSA release over time per each group is marked with asterisks (p<0.05) 
for the time points at (E) 48h and (F,G) at 7 days. 
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almost identical. As expected, the SKD group showed a burst release, up to 80% lost within the first 12 hours. In 
addition, LD exhibited a considerably faster release rate compared to HD with complete release plateauing at day 
18 compared to day 50 for HD samples. Similar release kinetics were found for both LD and HD and the 
corresponding LD/HD ADS (Figure 4.6B). The results suggested a negligible contribution of the collagen 
scaffold to the release kinetics when the microspheres were adsorbed on its surface. Considering the loss of 
PLGA-pSi from ADS, presented in the supporting information session, it is reasonable to believe that the similar 
release kinetics of free LD/HD and LD/HD ADS could be attributed to the massive loss of PLGA-pSi (82.5%) 
from the ADS scaffolds within the first two weeks. The release from LD/HD INT was significantly delayed 
compared to all other groups (Figure 4.6C), confirming the contribution of the collagen matrix in modulating the 
release kinetics by creating an additional coating layer over the microspheres. As expected, the release of BSA 
from HD INT scaffold exhibited a slower release rate compared to the corresponding free HD (Figure 4.6D). The 
quantification of the total mass of BSA released at the individual time points revealed that significant amounts of 
BSA were discharged by LD SKD and HD INT as early as 48 hours (5x and 7x respectively) (Figure 4.6E). After 
seven days, free and LD ADS demonstrated similar cumulative release (~78%), while INT released 50% and 35% 
of BSA from LD and HD respectively (Figure 4.6F). LD and HD INT scaffolds showed substantially different 
kinetics in the two layers (HD INT release rate being 50 percent slower than LD INT). While these results 
confirm the creation of temporal gradients of proteins, the observation that the BSA released from each layer, 
remained entrapped within its own layer, proved the spatial confinement of these protein regardless of their 
release during time. All together, these studies demonstrated that the integration of microparticles within the 
collagen scaffold matrix played an important role in controlling the staged release and spatial retention of two 
reporter proteins within the two separate compartments of the scaffold.  
 
4.4. Conclusions  
With this study we present a novel approach for the creation of multiscale biomimetic scaffold, capable of 
generating spatial and temporal protein patterns. The result was achieved by leveraging the natural ability of the 
collagen matrix to interact with PLGA-psi microspheres, effectively constructing a simple and tunable system for 
various tissue engineering applications. Optimizing the synthesis of monolithic multilayered collagen scaffolds, 
we stably integrated PLGA-pSi within the collagen matrix without altering collagen’s nano- and micro- structure. 
The results demonstrate that this modular approach to fabricate multi-compartment scaffolds allow for tissues 
mimicry at a multiscale level. At the nanoscale, the type I collagen conserved its fibrillar structure and typical D-
bands appearance, while the pSi nanostructure allowed the loading and release of reporter proteins. At the 
microscale, the PLGA coating of pSi created a composite delivery platform for the tunable release of the reporter 
proteins, while the collagen coating on PLGA-pSi enabled for their spatial confinement in the scaffold. Finally, at 
the macroscale, all these elements combined, without altering the feature of the material, such as pore size, 
porosity and swelling upon PLGA-pSi integration. pSi, PLGA and collagen boundaries contributed to 
accomplishing the temporal patterning of the proteins in the multi-layered scaffold, through a triple controlled 
release, enabling for the zero-order release kinetics of reporter protein up to 50 days. The release of controlled 
amounts of drugs over long periods of time would favor on-scaffold regeneration while avoiding adverse effects 
due to the diffusion of high doses of therapeutic molecules in the tissues surrounding the scaffold. By grafting 
distinct sets of PLGA-pSi composites, one can envision the creation of multiple unique biochemical niches within 
a 3D biomimetic scaffold, while protecting the payload and the delivery system from the cellular and enzymatic 
attach of cells of the immune system (mainly macrophages) and from the surgical procedures (washing, 
debridement, bleeding, fluid aspiration) applied during the implantation of the scaffold which challenge the 
integrity of the material.   
47 
 
4.5. References: 
 
 
 
 
1. Stevens, M.M. and J.H. George, Exploring and engineering the cell surface interface. Science, 2005. 310(5751): p. 
1135-1138. 
2. Oliveira, M.B., et al., Combinatorial On‐Chip Study of Miniaturized 3D Porous Scaffolds Using a Patterned 
Superhydrophobic Platform. Small, 2012. 
3. Lutolf, M. and J. Hubbell, Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis 
in tissue engineering. Nat Biotechnol, 2005. 23(1): p. 47-55. 
4. Ben-David, D., et al., Low dose BMP-2 treatment for bone repair using a PEGylated fibrinogen hydrogel matrix. 
Biomaterials, 2013. 
5. Madry, H., et al., Transforming Growth Factor Beta-Releasing Scaffolds for Cartilage Tissue Engineering. Tissue 
Eng. Pt B: Rev, 2013. 
6. Jakobsen, R.B., et al., Chondrogenesis in a hyaluronic acid scaffold: comparison between chondrocytes and MSC 
from bone marrow and adipose tissue. Knee Surgery, Sports Traumatology, Arthroscopy, 2010. 18(10): p. 1407-
1416. 
7. Wang, C.-C., et al., A highly organized three-dimensional alginate scaffold for cartilage tissue engineering 
prepared by microfluidic technology. Biomaterials, 2011. 32(29): p. 7118-7126. 
8. Schultz, G.S. and A. Wysocki, Interactions between extracellular matrix and growth factors in wound healing. 
Wound Repair Regen., 2009. 17(2): p. 153-162. 
9. Geiger, M., R.H. Li, and W. Friess, Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Del Rev, 
2003. 55(12): p. 1613-1629. 
10. Carragee, E.J., E.L. Hurwitz, and B.K. Weiner, A critical review of recombinant human bone morphogenetic 
protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J., 2011. 11(6): p. 471-491. 
11. Burkus, J.K., et al., Is INFUSE Bone Graft Superior to Autograft Bone? An Integrated Analysis of Clinical Trials 
Using the LT-CAGE Lumbar Tapered Fusion Device. J Spinal Disord Tech, 2003. 16(2): p. 113-122. 
12. Santo, V.E., et al., Controlled Release Strategies for Bone, Cartilage, and Osteochondral Engineering—Part II: 
Challenges on the Evolution from Single to Multiple Bioactive Factor Delivery. Tissue Eng. Pt. B-Rev., 2013. 
13. Choi, D.H., et al., Dual Growth Factor Delivery Using Biocompatible Core–Shell Microcapsules for Angiogenesis. 
Small, 2013. 
14. Tabata, Y., Tissue regeneration based on growth factor release. Tissue Eng., 2003. 9(4, Supplement 1): p. 5-15. 
15. Drinnan, C.T., et al., Multimodal release of transforming growth factor-β1 and the BB isoform of platelet derived 
growth factor from PEGylated fibrin gels. J. Controlled Release, 2010. 147(2): p. 180-186. 
16. Tasciotti, E., et al., Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic 
applications. Nat Nanotechnol, 2008. 3(3): p. 151-157. 
17. Sun, W., et al., Nano‐to Microscale Porous Silicon as a Cell Interface for Bone‐Tissue Engineering. Advanced 
materials, 2007. 19(7): p. 921-924. 
18. Sun, W., et al., Nano- to Microscale Porous Silicon as a Cell Interface for Bone-Tissue Engineering. Advanced 
materials, 2007. 19(7): p. 921-924. 
19. Anglin, E.J., et al., Porous silicon in drug delivery devices and materials. Advanced drug delivery reviews, 2008. 
60(11): p. 1266-1277. 
20. Whitehead, M.A., et al., High-porosity poly (ε-caprolactone)/mesoporous silicon scaffolds: calcium phosphate 
deposition and biological response to bone precursor cells. Tissue Engineering Part A, 2008. 14(1): p. 195-206. 
21. Fan, D., et al., The role of nanostructured mesoporous silicon in discriminating in vitro calcification for electrospun 
composite tissue engineering scaffolds. Nanoscale, 2011. 3(2): p. 354-361. 
22. Martinez, J.O., et al., Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. 
Biomaterials, 2013. 34(33): p. 8469-8477. 
23. Fan, D., et al., Mesoporous Silicon-PLGA Composite Microspheres for the Double Controlled Release of 
Biomolecules for Orthopedic Tissue Engineering. Adv. Funct. Mater., 2012. 22(2): p. 282-293. 
24. Spiller, K.L., et al., A novel method for the direct fabrication of growth factor-loaded microspheres within porous 
nondegradable hydrogels: Controlled release for cartilage tissue engineering. J. Controlled Release, 2012. 157(1): 
p. 39-45. 
25. Son, J.S., et al., Porous hydroxyapatite scaffold with three-dimensional localized drug delivery system using 
biodegradable microspheres. J Controlled Release, 2011. 153(2): p. 133-140. 
48 
 
26. Wei, G., et al., The enhancement of osteogenesis by nano-fibrous scaffolds incorporating rhBMP-7 nanospheres. 
Biomaterials, 2007. 28(12): p. 2087-2096. 
27. Abbas, A.K., A.H. Lichtman, and S. Pillai, Basic immunology: functions and disorders of the immune system. 2012: 
Saunders WB. 
28. Maynes, R., Structure and function of collagen types. 2012: Elsevier. 
29. Chiappini, C., et al., Tailored Porous Silicon Microparticles: Fabrication and Properties. ChemPhysChem, 2010. 
11(5): p. 1029-1035. 
30. De Rosa, E., et al., Agarose surface coating influences intracellular accumulation and enhances payload stability of 
a nano-delivery system. Pharm Res, 2011. 28(7): p. 1520-30. 
31. Tampieri, A., et al., Design of graded biomimetic osteochondral composite scaffolds. Biomaterials, 2008. 29(26): p. 
3539-46. 
32. Parodi, A., et al., Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like 
functions. Nat Nanotechnol, 2012. 
33. Tan, H., et al., Gelatin/chitosan/hyaluronan scaffold integrated with PLGA microspheres for cartilage tissue 
engineering. Acta Biomater., 2009. 5(1): p. 328-337. 
34. Martinez, J.O., et al., Evaluation of Cell Function Upon Nanovector Internalization. Small, 2013. 9(9-10): p. 1696-
1702. 
35. Danhier, F., et al., PLGA-based nanoparticles: an overview of biomedical applications. J. Controlled Release, 2012. 
161(2): p. 505-522. 
36. Anderson, J.M. and M.S. Shive, Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug 
Deliv Rev, 1997. 28(1): p. 5-24. 
37. Fan, D., et al., Mesoporous Silicon-PLGA Composite Microspheres for the Double Controlled Release of 
Biomolecules for Orthopedic Tissue Engineering. Advanced Functional Materials, 2012. 22(2): p. 282-293. 
38. Badylak, S.F., D.O. Freytes, and T.W. Gilbert, Extracellular matrix as a biological scaffold material: structure and 
function. Acta Biomater., 2009. 5(1): p. 1-13. 
39. Cheema, U., M. Ananta, and V. Mudera, Collagen: applications of a natural polymer in regenerative medicine. 
Regenerative Medicine and Tissue Engineering—Cells and Biomaterials. Eberli D, Ed. In Tech, 2011: p. 287-300. 
40. H. Lodish, A.B., S.L. Zipursky, P. Matsudaira, D. Baltimore, J. Darnell, Molecular Cell Biology, ed. N.Y.W.H. 
Freeman. 2000. 
41. Erickson, B., et al., Nanoscale structure of type I collagen fibrils: Quantitative measurement of D‐spacing. Biotech. 
J., 2013. 8(1): p. 117-126. 
42. Barker, T.H., The role of ECM proteins and protein fragments in guiding cell behavior in regenerative medicine. 
Biomaterials, 2011. 32(18): p. 4211-4214. 
43. Payne, K. and A. Veis, Fourier transform IR spectroscopy of collagen and gelatin solutions: deconvolution of the 
amide I band for conformational studies. Biopolymers, 1988. 27(11): p. 1749-1760. 
44. Camacho, N.P., et al., FTIR microscopic imaging of collagen and proteoglycan in bovine cartilage. Biopolymers, 
2001. 62(1): p. 1-8. 
45. Courtney, T., et al., Design and analysis of tissue engineering scaffolds that mimic soft tissue mechanical 
anisotropy. Biomaterials, 2006. 27(19): p. 3631-3638. 
46. O’Brien, F.J., et al., Influence of freezing rate on pore structure in freeze-dried collagen-GAG scaffolds. 
Biomaterials, 2004. 25(6): p. 1077-1086. 
47. Gavenis, K., et al., BMP-7-loaded PGLA microspheres as a new delivery system for the cultivation of human 
chondrocytes in a collagen type I gel: the common nude mouse model. Int. J. Art. Org., 2010. 33(1): p. 45-53. 
48. Srouji, S., et al., Slow-release human recombinant bone morphogenetic protein-2 embedded within electrospun 
scaffolds for regeneration of bone defect: in vitro and in vivo evaluation. Tissue Eng. Pt. A, 2010. 17(3-4): p. 269-
277. 
49. Seidi, A., et al., Gradient biomaterials for soft-to-hard interface tissue engineering. Acta Biomater., 2011. 7(4): p. 
1441-1451. 
 
49 
 
CHAPTER 5 
 
 
CAMOUFLAGING OF DELIVERY 
SYSTEMS IN 3D BIOMIMETIC 
SCAFFOLDS  
 
 
 
 
5.1. Introduction:  
Biomaterials mimicking the structure and composition of the extracellular matrix (ECM) are capable of acting as 
inductive templates for the formation of site-specific functional tissues [7]. Collagen, the basic structural element 
for most connective tissues, plays a prominent role in maintaining the structural integrity of tissue architecture, 
and it has been successfully used in several applications of tissue engineering [1-3]. Collagen is a highly dynamic 
component of the ECM which contributes basic information for cell attachment [4], migration [5], organization 
[6] and macrophages have shown to favorably respond to it, contributing to collagen-based materials’ integration 
[7]. This reciprocal interaction between cells and matrix is key for tissue regeneration and the consequent tissue 
homeostasis [8]. However, collagen alone lacks the ability to recapitulate the complexity of tissues’ milieu, 
therefore the addition of bioactive factors is needed for the specific application [9]. The functionalization of 
biomimetic scaffolds with delivery systems [10] has become an attractive option for many approaches of 
regenerative medicine that require the in situ delivery of drugs and growth factors [11, 12]. Encapsulating 
therapeutic molecules in polymer particles offers considerable advantages, including tailoring of well controlled 
release kinetics, protection from degradation and temporo-spatial targeting [11, 13]. Unfortunately, these drug 
delivery systems, in vivo, usually trigger the 
recruitment of cells of the immune system (e.g. 
neutrophils and macrophages)[14, 15]  which 
may lead to an unwanted sequence of events, 
including acute and/or chronic response, 
foreign body reaction and fibrous tissue 
formation [16]. It has been established that 
macrophages appear in the site of the injury, in 
the early stages (1-3 days) [17-19]. Tissue 
remodeling following implantation is also 
associated with an increased macrophage 
activity [20]. The size [21], shape [22] and 
physico-chemical properties (rigidity, 
charge)[23, 24] of the material affect the 
activation of internalization by macrophages and ultimately the intensity and duration of the inflammatory 
process. Avoiding early detection and phagocytosis of the delivery systems from engineered scaffolds is crucial to 
ensure the proper temporal and spatial control over the release of their payload. In fact, in order to obtained the 
desired outcome, it is fundamental that the therapeutic molecule is released with the proper kinetic and in the 
target tissue compartment to be effective. Poly(dl-lactide-co-glycolide acid (PLGA) microspheres are FDA 
approved delivery systems [25], that can be synthesized through simple and easily scalable processes [26]. They 
have also been integrated in  scaffolds for tissue engineering to provide a further level of control in the release of  
the payload of interest [27]. However, when their diameter is below 10-15 µm in size, they are efficiently 
Figure 5.1 - Schematic showing how the biomimetic scaffold functionalized 
with stealth microspheres for the release of proteins (A). Panel B shows 
how the collagen coating (blue) could prevent macrophages (green) from 
detecting the delivery systems (red) for the controlled release of proteins 
(red dots).   
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internalized by phagocytic cells [18]. Recently, injectable polymer-based delivery systems have been coated with 
components of the ECM (i.e gelatin and collagen) [28], aiming at reducing the immune response and clearance 
from the body, while increasing payload stability [29]. According to these findings, we recently developed an 
innovative approach for the functionalization of 3D biomimetic scaffolds, by integrating MS in the pores’ walls of 
a type I collagen scaffold, thus enabling spatial and temporal control over MS and their payload [11]. The 
hypothesis of this study is that by fully embedding MS below 5 µm in a highly structured and fibrous collagen-
based scaffold (camouflaging), it is also possible to 
prevent their early detection and clearance by 
macrophages. We also investigated whether such 
camouflage could efficiently reduce the production 
of key inflammatory molecules, while preserving 
the release kinetics of MS payload. Schematic in 
Figure 5.1 depicts the rationale of this study, 
showing how the collagen coating (blue) could act 
screening MS (red) to macrophages (green).  
 
5.2. Materials and Methods: 
5.2.1. MS synthesis:  
PLGA 50:50 (LACTEL) was dissolved in 
dichloromethane (DCM) (Sigma-Aldrich) at a 
concentration of 100 mg/ml. Tetramethylrhodamine 
(TRITC) (Sigma-Aldrich) was added to 1 ml of 
PLGA in DCM, and mix at the PLGA solution at a 
concentration of 10 μg/ml. The organic phase was 
homogenization at 6000 rpm with the aqueous 
solution of poly (vinyl alcohol) (PVA) (Fisher 
Scientific) (10 ml, 5 mg/ml) to synthesize MS with 
a diameter inferior to 5µm. The emulsions were 
dropped into an aqueous solution (50 mL) 
containing PVA (2.5 mg/ml). The resulting 
suspension was stirred for 6 h to allow the 
evaporation of the organic solvent. For the release 
study we fabricated MS loaded with Fluorescein 
isothiocyanate (FITC) – Bovine Serum Albumin (FITC-BSA) (Sigma Aldrich). FITC-BSA was mixed (1mg/ml) 
to the solution of PLGA in DCM, and the synthesis was carried out as reported above.   
5.2.2. Scaffolds fabrication:  
Type I collagen (Sigma-Aldrich) was dissolved in acetate buffer (pH 3.5). The resulting collagen gel (containing 
1g of dry collagen) was precipitated by the addition of a solution of sodium hydroxide 0.1 M, to pH 5.5. The 
collagen slurry was washed three times with DI water. The collagen was cross-linked through dispersion for 48 h 
in a 1,4-butanediol diglycidyl ether (BDDGE) (Sigma-Aldrich) aqueous solution (2.5 mM) [14]. The cross-linked 
collagen was washed 3 times in DI water. The cross-linked collagen was suspended in DI water (5 mL), and 2 
groups of collagen scaffolds were fabricated: integrated with MS (MS INT) or with MS simply adsorbed into the 
scaffold (MS ADS). MS INT scaffolds were fabricated blending MS (2 wt%) with cross-linked collagen. A 
dispersion of MS (3 mg/mL) in DI water was added during the fabrication of the scaffolds, at its slurry state. The 
material was freeze-dried with a controlled freezing ramp from 25 °C to -25 °C and a heating ramp from -25 °C to 
25 °C in 50 min under vacuum conditions (P = 0.20 mbar), and porous collagen scaffolds (20mm
3
) were 
produced. The same amount of MS was adsorbed on an unmodified collagen scaffolds, by soaking a collagen 
sponge in the particle suspension. These scaffolds were ultimately freeze-dried, as described. Cylindrical scaffolds 
of 8 mm in diameter and 1 mm thick were produced and characterized.  
5.2.3. Macrophage seeding on MS INT and MS ADS:  
Figure 5.2 - SEM images at 24, 48h and 72h of J774 incubated with MS 
(A); Scale bar 2 μm. 3D rendering of Z-stacks acquired by confocal laser 
microscopy images of 2D C, incubated with MS at 72h, to identify the 
single particles internalized (B); Scale bars 5 μm. Quantification of the 
average number of particles/cell (C) and fold increase in cellular 
volume, at 72h, after internalization of MS (D). 
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Internalization of MS in the scaffolds was assessed both with J774, and bone marrow-derived macrophages 
(BMDM). BMDM were isolated as previously described, and in accordance with institutional animal usage 
guidelines [27]. Briefly, after sacrificing BALB/c mice femurs were cleaned of surrounding tissues and cut at both 
ends. The cavity was flushed with complete media, using a 5 mL syringe and a 25-gauge needle. Bone marrow 
cells were mechanically separated into single-cell suspension, filtered and plated in media supplemented with 
macrophage colony-stimulating factor (10ng/ml). 3·105 cells were seeded onto MS INT and MS ADS. Cells were 
deposited in a concentrated drop of 50 µl on top of the dry scaffolds and let adhere for 20 minutes, before media 
(up to 2 ml) was added. In the 2D simplified MS ADS 
model, the same cell density used in the scaffold was 
maintained. 
5.2.4. Flow cytometry:  
To quantify the percentage of cells (J774 and BMDM) 
internalizing MS at 24, 48 and 72h from seeding, scaffolds 
were digested with collagenase I (2mg/ml) (Life 
Technologies). Both cells and MS were recovered. Cell 
suspensions were filtered through 70 µm nylon mesh (BD 
Biosciences) to remove cell clumps and scaffold debris, and 
spun at 500 g for 5 min. Supernatants were removed and 
cell/particles pellets re-suspended in 1 mL of 70% EtOH. 
After fixation, cells were washed with FACS buffer (BSA 
0.1%). Cells were stained with F4/80 antibody conjugated 
with Alexa Fluor®488, according to vendor’s protocol 
(BioLegend) and resuspended in PBS. TRIC-labeled MS 
were used for this experiment. A minimum of 10,000 events 
per sample was analyzed using a BD LSR Fortessa™ cell 
analyzer (BD Biosciences, San Jose, CA). Data analysis was 
performed by FCS-Express (De Novo Software).  
 
 
5.2.5. Evaluation of the release kinetics from exposed and camouflaged MS:  
The release of the reporter protein FITC-BSA from MS, MS ADS, MS INT and MS INT seeded with 
macrophages J774 was assessed to evaluate whether the eventual internalization by macrophages would affect the 
release kinetics. The release was followed, as a proof of concept, up to 1 week. FITC-BSA release was quantified 
via Plate Reader (Perkin Elmer) at a wavelength of 488 nm. For the recovery of MS internalized by J774, cells 
were lysed by adding deionized water and freezing, to not affect MS and their payload [28].  
5.2.6. Statistical analysis:  
Statistical analysis was performed using Tukey’s multiple comparison test, with Graph Pad v6.02 for Windows. A 
value of p < 0.05 was considered statistically significant: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p<0.0001. 
Experiments have been performed in, at least, triplicates. Data are presented showing individual groups and 
respective ± SD.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 - SEM micrograph and 3D rendering of Z-stacks 
by confocal laser microscopy of MS ADS (A, B), compared to 
MS INT (C, D); Scale bars 5 μm and 100 μm respectively. 
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5.3. Results:  
 
5.3.1. MS internalization in 2D culture: 
MS were successfully prepared with an average diameter of 2 μm ± 0.38, and a Z potential of -8.04 (mobility -
0.8363). Initially, MS internalization was assessed in 2D conditions. SEM images of MS with J774 macrophages 
at 24h, 48h and 72h show how MS are massively engulfed already after 24h (Fig. 5.2A). Z-stacks acquired by 
confocal laser microscopy allowed to count the number of MS internalized per single cell at 72h (when saturation 
occurred), respect to 2D C (Fig. 5.2B). 3D intensity surface plot were obtained post-acquisition, to verify the 
internalization of the target MS (Fig. 5.2b). It resulted that J774 cells internalized an average of 9 (± 1.31) MS per 
cell (Fig. 5.2C). After 48h, the number of particles that have been internalized remained unvaried. No significant 
increase in toxicity was found. Cells internalizing MS appeared to duplicate in their volume, with an average fold 
increase of 2.3 (±0.13) respect to their control (Fig. 5.2D).  
5.3.2. Biomimetic scaffold functionalization with 
camouflaged microspheres: 
Scaffolds were optimized to be functionalized with 
approximately 10 MS/cell seeded. Fig. 5.3A shows a 
detail of the surface of MS ADS, in which MS are simply 
adsorbed and appear to be agglomerated. The 3D 
rendering obtained by confocal laser microscopy 
confirmed the observation (Fig. 5.3B). On the contrary, 
as shown in Fig. 5.3C the MS were fully integrated and 
homogeneously distributed in MS INT and were found in 
correspondence of the pore’ walls of the scaffold (Fig. 
5.3D). 
5.3.3. Evaluation of the internalization of 
camouflaged MS  
MS internalization by macrophages in MS ADS was 
firstly evaluated by confocal laser microscopy. Fig. 5.4A 
shows the comparison between 3D C and MS ADS 
scaffold, in which J774 (green) appear to have identified 
the MS (red) adsorbed on the scaffold pores’ walls 
(blue). On the contrary, MS INT were observed by SEM 
microscopy to better evaluate any change in J774’s 
morphology and to identify eventual MS hidden within 
the collagen matrix of the scaffold. Fig. 5.4B shows the 
comparison between 3D C and MS INT at different 
magnifications. At low magnification cells in MS INT 
appeared spread throughout the whole field of view 
similarly to the control, whereas those seeded onto MS 
ADS clustered around the MS. As shown in Fig. 5.4A, 
the most exposed MS were internalized by macrophages, 
suggesting the ability of these cells to detect them. On 
the contrary, MS embedded into the scaffolds (indicated 
by white arrows) were not detected, as pore’s walls are 
thicker than their diameter. These findings were further 
confirmed when the cut was cut transversally and the 
exposed MS were immediately identified by 
macrophages. 
Internalization was then assessed by flow cytometry and 
we found that at 24h the percentage of FITC/TRIC 
positive J774 in MS INT was 10-times lower than their 
Figure 5.4 - Confocal laser microscopy images of 3D C and MS ADS 
scaffolds (A); scale bar 50 μm. SEM micrographs of 3D C and MS 
INT (camouflaged MS indicated with white arrow) (B); scale bars 
100 and 10 μm. Percentage of cells internalizing MS in MS ADS and 
MS INT by flow cytometry (C). 
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control MS ADS. It became up to 15 times lower after 48h (Fig. 5.4C).  
SEM micrographs of MS INT BMDM showed no internalization (Fig. 5.5A) nor differences in cell morphology 
induced by their interaction with MS. BMDM appeared randomly distributed, similarly to the control group (3D 
C BMDM). Confocal laser microscopy further confirmed these observations. Images show cells attached to the 
surface of the collagen scaffold and MS lying underneath them (Fig. 5.5B). Interestingly, the percentage of cell 
that internalized MS correlated with that obtained with the J774 cell line. A10-folds decrease in internalization 
between MS ADS and MS INT was observed also with this cell line (Fig. 5.5C).  
 
5.3.4. Pro-inflammatory cytokine production:  
We further evaluated whether the collagen coating to avoid 
macrophage detection could also reduce the levels of some 
key pro-inflammatory cytokines (NO and TNF-α). 
Interestingly, the production of NO was found increased of 
one-fold when MS were not camouflaged (MS ADS) (Fig. 
5.6A). In MS ADS, NO production reached its maximum at 
48h (15.7 ± 2.01 µM), correlating with data obtained by flow 
cytometry, as J774 resulted to reach the maximum of MS 
internalization at the same time point. On the contrary, in 
MS INT NO levels were comparable to the control values 
(9.7 ± 0.71 and 10.7 ± 0.91 µM respectively) (Fig. 5.6A). At 
72h, the levels of TNF-α released by macrophages following 
the exposure to MS ADS were found significantly increased 
(3 and 2.5 fold, respectively) compared to their controls.  
Finally, after assessing the validity of our approach with 
J774 and to further validate the model in 3D, we tested the 
efficiency of MS INT to reduce macrophage detection of MS 
also with BMDM (Fig. 5.6B). Exposure of BMDM to the 
scaffolds did not show significant differences in the levels of 
cytokines produced when compared to J774 cells or to their 
controls (3D C BMDM).  
5.3.5. Effect of MS camouflage on the release kinetics of a 
reporter protein:  
To test whether MS INT could preserve the release kinetics 
of the payload respect to MS ADS the release of a reported 
protein (FITC-BSA) loaded in MS was monitored up to a 
week. The ratio cell/microspheres was optimized at 1:10 in 
all the experimental conditions, to be able to compare the 
cumulative releases obtained in the different conditions. At 
day 7 the cumulative release from MS INT resulted 45%, 
about half than that of MS ADS (100%) (Fig. 5.7A). MS 
INT and MS INT seeded with J774 (MS INT J774) showed 
comparable cumulative release and kinetics over time (45% 
and 41% respectively at 7 days). While from MS ADS 
seeded with J774 (MS ADS J774) only 16% of the protein 
was released, corresponding to a 6 fold decrease respect to 
MS ADS (Fig. 5.7A). We further characterized that at day 7 
in MS ADS J774 70% of the FITC BSA was found in the 
fraction of the macrophages, whereas only 5% of the protein was internalized by the cells in MS INT J774 (Fig. 
5.7B). Interestingly, in MS ADS only the 14% of MS were not internalized at 7 days, and this number was 
approximately 4-times increase in MS INT (54%).  
 
Figure 5.3 - SEM images of MS INT seeded with BMDM (A); 
Scale bar 20 and 10 μm. Confocal laser microscopy images 
of 3D C BMDM and MS INT BMDM (B); scale bar 10μm. 
Percentage of BMDM internalizing MS in MS ADS BMDM 
and MS INT BMDM, quantified by flow cytometry. 
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5.4. Discussion:  
The ideal scaffold to achieve tissue regeneration should be able to mimic the chemical and biochemical 
composition of the extracellular environment [29], to support cell recruitment, proliferation and differentiation 
[30]. Biomimetic scaffolds engineered with reservoirs of growth factors, chemokines or cytokines represent a 
promising strategy, and a plethora of delivery systems is now available for the storage and release of such proteins 
[31]. However, platforms able to overcome 
the clearance mediated by macrophages are 
crucial to ensure proper release kinetics of 
the bioactive molecules and guarantee the 
desired therapeutic effects [32]. In fact, since 
growth factors explicit their function in the 
extracellular environment, the internalization 
of the delivery systems mediated by the 
macrophages is responsible for the disruption 
of their functional mechanisms [33].  
In this study, we investigated whether 
camouflaging MS into a 3D collagen-based 
scaffold could offer an efficient method to 
prevent their internalization by macrophages 
and their consequent clearance from the 
implant.  
MS internalization by macrophages has been 
shown to depend on several physicochemical 
properties, such as size, charge and shape 
[19, 26]. For example, MS with diameter 
below 5 µm are known to be easily 
internalized by these cells [34]. Thus, as a 
prove of concept we tested MS with a 
diameter of 2 µm ± 0.38, and recapitulated in 
in vitro conditions the process of clearance 
occurring in vivo. Firstly, by using different 
concentrations of MS, we evaluated the maximum number of MS which could be internalized per J774. No 
significant differences were found neither in cell viability at increasing concentrations of MS, nor in the number 
of MS internalized, confirming previously published data [35, 36]. Each cell was able to internalize an average of 
9 MS. For this reason scaffolds were functionalized with approximately 10 MS per cell seeded, to potentially 
allow for the cells to clear all of them out from the scaffolds.  
To assess the validity of our approach, we initially analyzed the morphology of the J774 seeded onto MS INT and 
MS ADS and we found a cell cluster in MS ADS, which was mainly due to the presence of agglomerated MS on 
the surface of the scaffolds. This observation was further confirmed by the confocal microscopy images, which 
show the perfect co-localization of the clusters of MS (red) and J774 (green). These findings enforced our 
hypothesis that the collagen layer covering MS in MS INT could screen them, resulting in a more homogeneous 
cell distribution, comparable to that of 3D C. Flow cytometry quantitatively confirmed these results revealing a 10 
to 15 fold decrease in MS internalization in MS INT respect to MS ADS. Further corroborating these data, the 
uptake of MS by J774 from MS INT remained constant over time (2.5%) and not significantly differing from the 
control (MS ADS), while in MS ADS a burst MS uptake was quantified. This is particularly remarkable as it 
demonstrates the ability of the MS INT scaffold to camouflage MS for the window of time in which macrophages 
normally respond to the implant in vivo [37]. It is conceivable that macrophages did not detect the delivery 
systems when camouflaged in the scaffold, as they were just able to sense collagen’s chemical composition and 
topography, which is recognized as a component of the ECM. 
Figure 5.4 - Production of NO and TNF-α by J774 macrophages in response 
to MS ADS and MS INT respect to their control (3D C) up to 72h (A); NO and 
TNF-α production by BMDM on MS INT respect to the control, up to 72h (B).   
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In the biomedical research field, primary cell lines remain the cells of election for the in vitro test of any material 
or technology, as they present unique features which are inevitably lost in immortalized cells. Although J774 
display differences in behavior with respect to the native cell type, they represent a valuable tool for in vitro study 
of cell-material interfaces of this study. For these reasons the first part of our study was conducted with J774 
macrophages.  
Since tissue resident 
macrophages have been 
recently found to be the 
one responsible for the 
response to implants [38, 
39], we confirmed our 
findings with BMDM. The 
use of this cell type 
allowed us to closely 
recapitulate, in in vitro 
conditions, the in vivo 
response of macrophages 
to our MS INT scaffold. 
Interestingly, a slightly 
lower phagocytic activity 
was observed in BMDM 
respect to J774. This is 
possibly due to the 
intrinsic differences 
between the two cell lines, including their size. In fact, analyzing the Z-stack acquisitions of single J774 and 
BMDM by confocal microscopy, BMDM resulted 15% smaller than J774 in volume (data not shown). This might 
explain the reduced number of MS that BMDM could internalize. In addition to this it is possible that this 
phenomenon reflects the different nature of the two cell lines (the immortalized J774 and the primary BMDM) 
[40], thus affecting their phagocytic activity [41].  
An important consequence of MS internalization by macrophages is the triggering of the inflammatory cascade, 
which involves production of pro-inflammatory cytokines and can lead to implants’ failure [32]. However, the 
new paradigm based on the anti-inflammatory role of macrophages [42] also highlighted the relevance of 
macrophage response to biomaterials to initiate the remodeling of the scaffold, ultimately leading to tissue repair 
[5]. Therefore, we evaluated the potential of this camouflaging approach to diminish the production of pro-
inflammatory cytokines by macrophages following the interaction with the scaffold. In particular, among the pro-
inflammatory molecules, we selected NO and TNF-α that are important drivers of fibrosis, being involved in 
fibroblast proliferation and collagen deposition [43]. Data obtained supported our hypothesis, as the camouflage 
of MS by the scaffold prevented the release of pro-inflammatory molecules by both the cell lines.   
To finally prove the validity of our approach, we followed the release of a reporter protein (FITC-BSA) over a 
week, to understand whether the release kinetics was maintained or affected by macrophages. 
According to our previous findings, the secondary coating created by the collagen matrix on the MS, became a 
further level of control over the release of proteins, allowing for a zero-order release kinetic [14]. Instead, due to 
the massive initial burst release in MS ADS, FITC-BSA was completely released within a week. When MS ADS 
were exposed to J774, the overall release at 7 days drastically decreased possibly due to the fact that MS were up-
taken by the cells. On the contrary, the release from MS INT with or without J774 showed comparable kinetics.  
In summary, this study demonstrated the potential of our platform to prevent the clearance mediated by 
macrophages of proteins or drugs’ reservoirs from a 3D biomimetic scaffold, while reducing the production of 
key pro-inflammatory cytokines. 
 
 
 
Figure 5.5 - Cumulative release of BSA up to 1 week, from MS ADS, MS INT, compared to the 
corresponding samples incubated with J774 macrophages (MS ADS J774 AND MS INT J774 
respectively) (A); corresponding quantifications of BSA in the particles not internalized (MS), 
found inside macrophages (J774) or Released for MS ADS J774 and MS INT J774 samples (B). 
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5.5. Conclusions: 
In the present study we evaluated whether the integration of MS in type I collagen scaffold could provide an 
efficient and simple method for particle camouflage to prevent their internalization by macrophages and 
consequently reduce the production of pro-inflammatory cytokines, and to preserve the release kinetics of the 
payload. Herein, we provide striking evidences regarding the potential of this platform to: (i) escape the 
internalization by macrophages, (ii) enable the reduction of pro-inflammatory cytokines production by 
macrophages, and (iii) preserve the expected release kinetics engineered with the delivery platform. The 
reported findings can guide the rational design of functionalized scaffolds achieving the desired level of 
internalization of MS by immune cells. This study could significantly impact tissue engineering 
approaches, in which a tightly controlled confinement of the bioactive molecules is required, to achieve 
tissue healing without triggering the inflammatory response. 
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CHAPTER 6 
 
 
CONCLUSIONS 
 
 
 
In summary, firstly, the nanostructured composite microspheres PLGA-pSi were developed. Their full 
tunability was demonstrated. This kind of composite carrier combined the advantages of mesoporous 
structures to be loaded with high amount of proteins, due to their high surface area, and the plasticity and 
tailorability of polymers. As a proof of concept, the formulation which accomplished the most controlled 
and sustained release was tested in vivo, to demonstrate the temporal and spatial control over the release of 
the payload. However, depending on the application, it is possible to envision the use of other formulations, 
and also the combined use of multiple formulations of PLGA-pSi. They also resulted greatly advantageous 
by being injectable, which would allow for an easy administration of a molecule of interest, once a month, 
while showing low toxicity. These results assessed in vivo that PLGA-pSi represents a robust, reproducible 
and scalable carrier for applications of tissue regeneration. 
Secondly, a novel approach for the creation of multiscale biomimetic scaffold, capable of generating spatial 
and temporal protein patterns was designed. The result was achieved by leveraging the natural ability of 
the collagen matrix to interact with PLGA-psi microspheres, effectively constructing a simple and tunable 
system for various tissue engineering applications. Optimizing the synthesis of monolithic multilayered 
collagen scaffolds, we stably integrated PLGA-pSi within the collagen matrix without altering collagen’s 
nano- and microstructure. The results demonstrated that this modular approach to fabricate multi-
compartment scaffolds allow tissue mimicry at a multiscale level. At the nanoscale, the type I collagen 
conserved its fibrillar structure and typical D-bands appearance, while the pSi nanostructure allowed the 
loading and release of reporter proteins. At the microscale, the PLGA coating of pSi created a composite 
delivery platform for the tunable release of the reporter proteins, while the collagen coating on PLGA-pSi 
enabled for their spatial confinement in the scaffold. Finally, at the macroscale, all these elements 
combined, without altering the feature of the material, such as pore size, porosity and swelling upon PLGA-
pSi integration. pSi, PLGA and collagen contributed to accomplishing the temporal patterning of the 
proteins in the multi-layered scaffold, through a triple controlled release, enabling for zero-order release 
kinetics of reporter proteins up to 50 days. The release of controlled amounts of drugs over long periods of 
time would favor on-scaffold regeneration while avoiding adverse effects due to the diffusion of high doses 
of therapeutic molecules in the tissues surrounding the scaffold. By grafting distinct sets of PLGA-pSi 
composites, one can envision the creation of multiple unique biochemical niches within a 3D biomimetic 
scaffold, while protecting the payload and the delivery system from the cellular and enzymatic attach and 
from the surgical procedures (washing, debridement, bleeding, fluid aspiration) applied during the 
implantation of the scaffold which challenge the integrity of the material. 
Lastly, it was investigated whether the integration of PLGA-pSi microspheres in type I collagen scaffold 
could provide an efficient and simple method for particle camouflage to prevent their internalization by 
macrophages and consequently reduce the production of pro-inflammatory cytokines, and to preserve the 
release kinetics of the payload. It was provided striking evidences regarding the potential of this platform 
to: (i) escape internalization by macrophages, (ii) enable the reduction of pro-inflammatory cytokine 
production by macrophages, and (iii) preserve the expected release kinetics engineered with the delivery 
platform. The reported findings can guide the rational design of functionalized scaffolds achieving the 
desired level of internalization of PLGA-pSi microspheres by immune cells.  
All together, this study could significantly impact tissue engineering approaches, in which a tightly 
controlled confinement of the bioactive molecules is required, to achieve tissue healing without triggering 
the inflammatory response. 
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